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Abstract 
Purpose: To describe the experience of managing relapsing-remitting multiple sclerosis 
among adult women users of injectable disease modifying drugs, including day-to-day 
management, medication beliefs, and health care provider influence. 
Rationale/Significance of the study: Approximately 85% of the 400,000 Americans with 
multiple sclerosis have relapsing-remitting multiple sclerosis (RRMS), characterized by 
unpredictable relapses and partial or full remissions of neurological symptoms. 
Untreated, RRMS may progress to permanent, irreversible disability and decreased 
quality of life. Current guidelines recommend immediate and sustained treatment with 
injectable disease modifying drugs (DMDs). However, despite pronounced modest 
benefits, approximately 30%-62% of patients are not undergoing DMD therapy. A small 
number of quantitative studies have identified factors that predict adherence to injectable 
DMDs. However, little is known about injectable DMDs from patients’ perspectives. It is 
important to develop an understanding of the experience of managing RRMS among 
adult users of injectable DMDs in order for health care providers to provide ongoing 
education, counseling, and support. 
Organizing Framework: The framework, Beliefs About Medicines, was used to guide the 
study. 
Design: Qualitative descriptive design. 
Setting: Data were collected from adult women with RRMS who received care from an 
MS clinic, a neurology practice, and through snowball sampling. 
Sample: Purposive and theoretical sampling was used to recruit 32 women with RRMS. 
Maximum variation sampling ensured the appropriate breadth and depth of experiences. 
  x  
Women currently undergoing injectable DMD therapy (n = 25), as well as women who 
either discontinued (n = 6), or never used (n = 1) injectable DMDs were interviewed. 
Methods: A qualitative descriptive design was utilized. Verification occurred through 
trustworthiness of data, including rich, thick description from qualitative interviews; field 
notes and memoing; and member checks. Simultaneous data collection, analysis, and 
interpretation facilitated interview revision in order to elicit or expand emerging themes. 
Content analysis inductively derived themes and patterns within and across categories. 
Participant quotes substantiated particular themes. Confirmability of the data analysis 
process was undertaken in consultation with the research advisor. 
Implications: Findings elucidated adult women’s subjective experiences concerning 
management of RRMS among users of DMDs, including day-to-day management, 
medication beliefs, and health care provider influence.  Results from this study can be 
used to educate, counsel, and support women in the management of RRMS.
  xi  
Chapter I 
Introduction 
Approximately 85% of patients diagnosed with multiple sclerosis (MS) 
experience the relapsing-remitting subtype (Lublin & Reingold, 1996). Close to 300,000 
individuals living in the United States with this autoimmune neuroinflammatory illness 
face periods of transient, unpredictable, and potentially disabling symptomatology, as 
well as an uncertain illness trajectory (Anderson, et al., 1992).  Furthermore, researchers 
estimate that up to 90% of individuals with relapsing-remitting multiple sclerosis 
(RRMS) may progress to a more serious and debilitating form of the disease 
(Weinshenker, et al., 1989a). The unstable nature of RRMS can lead to lost revenues due 
to increased work absences (Gedizliogu et al., 2000; Kobelt, Berg, Atherly, & 
Hadjimichael, 2006), an abrupt end to employment  (Grima et al., 2000; Kobelt, Berg, 
Lindgren, Fredrikson, Jonsson, 2006; O’Day, 1998), and increased use of health care 
resources (Miltenburger & Kobelt, 2002; National Multiple Sclerosis Society, 2002a; 
Phillips, 2004; Pope, Urato, Kulas, Kronick, & Gilmer, 2002).  As a result, the impact of 
RRMS can be physically, financially, and emotionally devastating, and lead to a poor 
quality of life (Grima et al., 2000; McCabew & De Judicibus, 2005; Merkelbach, 
Sittinger, & Koenig, 2002; Parkin, McNamee, Miller, Thomas, & Bates, 2000; Solari & 
Radice, 2001). 
Injectable DMDs (formerly called injectable immune modulators), introduced in 
the 1990’s, have been instrumental in minimizing or eradicating symptoms, lengthening 
remissions, and retarding the progression of RRMS (Fernandez et al, 2003; Galetta, 
Markowitz, & Lee, 2002; Jacobs et al, 1996; Johnson et al, 1995; Paty, Li, the UBC 
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MS/MRI study group, & the IFNB Multiple Sclerosis Study Group, 1998). Although not 
a cure, the use of injectable DMD therapy has resulted in improved quality of life for 
some individuals with RRMS (Arnoldus, et al., 2000; Hemmet, et al., 2004; Isaksson, 
Ahlstrom, & Gunnarsson, 2005; Kobelt, et al, 2006;  Lily, McFadden, Hensor, Johnson, 
& Ford, 2006; Zivadinov et al., 2003). Yet, despite the pronounced benefits of  injectable 
DMD therapy, an estimated 30% (Lo, Hadjimichael, & Vollmer, 2005) to 62% 
(Avasarala, O’Donovan, Roach, Camacho, & Feldman, 2007) of patients with RRMS are 
not currently using it. Moreover, several studies have indicated that many patients who 
are engaged in injectable DMD therapy abandon therapy within the first two years 
(Munschauer & Tyree, 2004; NARCOMS News, 1999; PharMetrics Patient Centric 
Database, data on file, 2000-2002; Rio, et al., 2005; Ruggieri, et al, 2003). The most 
common reasons given for treatment discontinuation are worsening symptoms 
(Hadjimichael & Vollmer, 1999), perceived lack of drug efficacy (Onesti et al., 2003; 
O’Rourke & Hutchinson, 2005; Tremlett & Oger, 2003), and treatment side effects 
(Daugherty, Butler, Mattingly, & Ryan, 2005). 
A small number of quantitative studies in the literature measured factors that 
influence patients’ adherence to injectable DMD therapy , including self-efficacy, hope, 
physician support, previous use of injectable DMDs (Fraser, Hadjimichael, & Vollmer, 
2001), mood ( Mohr et al., 2000), pretreatment expectations, and post-injection anxiety 
(Mohr, Boudewyn, Likosky, Levine, & Goodkin, 2001). 
A phenomenological study of patients with RRMS (n = 15) undergoing treatment 
(with  IFNB-1a) focused on patients’ physical, cognitive, and emotional adaptation to the 
illness and treatment (Miller & Jezewski, 2001). A more recent qualitative study by 
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Johnson and colleagues (2006) focused on perspectives regarding the injectable DMDs 
among patients with MS (n = 18). Patients who were using injectable DMDs (n = 11) 
described positive (disease stability, feeling of control) and negative (cost of medication, 
fear, and uncertainty) aspects of treatment. Patients who were not on therapy, including 
those who discontinued use (n = 2) and those who never started (n = 5), described reasons 
for non-use, including fear of needles, lack of active disease, fear of side effects, and cost. 
There are several differences between the study by Johnson et al (2006) and this 
researcher’s dissertation study. First, the study sampled 18 participants from a larger pool 
of volunteers. A small number of the participants had a form of MS other than RRMS 
(primary progressive, n = 1; secondary progressive n = 1). Further, the study included 
men (n = 2). In addition, perspectives about ‘opting out’ of treatment were recorded from 
all non-users of injectable DMDs, making it difficult to distinguish perspectives of those 
who had discontinued use from those who had never used the medication. Finally, the 
study only studied perspectives related to use or non-use of injectable DMDs. Little detail 
is available about patients’ subjective experiences of managing RRMS among users and 
nonusers of injectable DMDs, including day-to-day management, barriers to treatment, 
personal medication beliefs, and the influence of health care providers. Therefore, the 
purpose of this qualitative descriptive study was to develop a clear understanding of the 
experience of managing RRMS among adult women users and nonusers of injectable 
DMD therapy. 
  3  
The specific aims of the proposed research were to: 
1) Describe the subjective experience of the day-to-day management of RRMS 
among adult women who were currently using injectable DMDs, had never used 
injectable DMD, or had stopped using injectable DMDs. 
2) Examine treatment beliefs, including treatment necessity and perceived concerns, 
related to injectable DMD therapy among patients with RRMS who were using or 
not using injectable DMD therapy. 
3) Examine the influence of health care providers on treatment beliefs and 
management of injectable DMD therapy among adult patients with RRMS who 
were using or not using injectable DMD therapy. 
Background and Significance 
Incidence and Prevalence 
Multiple sclerosis (MS) is a chronic neuroinflammatory disease that affects most 
individuals between the ages of 15 and 45 (Jacobson, Gange, Rose, & Graham, 1997). 
Approximately 1.5 million individuals worldwide live with MS, and, in the United States, 
more than 400,000 cases have been identified (National Multiple Sclerosis Society, 
2004a).  Each year an estimated 8,500 to 10,000 new cases are diagnosed (Jacobson et 
al., 1997). MS is more prevalent among Caucasians, and women are more than twice as 
likely to be affected as men (Anderson et al, 1992). 
The cause of MS is unknown, although several theories continue to be explored, 
including genetics (Ebers & Sadovnick, 1994; Prat & Martin, 2002; Ransohoff, 2000), 
environment (Kurtzke, 1988; Pugliati, Sotgiu, & Rosati, 2002), infectious agents (Cook 
& Dowling, 1980; Kurtzke, 1993) and biochemical factors (Casetta & Granieri, 2000; 
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Kurtzke, 1993; Noseworthy, Lucchinetti, Rodriquez, & Weinshenker, 2000). At the 
present time, there is no known cure for MS. Although MS does not shorten an adult’s 
lifespan, its disabling nature can affect quality of life for many individuals. It is the third 
most common neurological cause of disability among young people (ages 20-40) (Salan, 
2003). 
Relapsing Form of MS 
  MS is now believed to be a heterogeneous disease, with diverse pathological 
processes and clinical presentations occurring among and within persons at any given 
time (Galetta, Markowitz, & Lee, 2002; Lucchinetti et al., 2000; Ransohoff, 2000; 
Weinshenker et al, 1989b). Four subtypes of MS have been distinguished: relapsing-
remitting, primary progressive, secondary-progressive, and relapsing-progressive MS 
(see Table 1 for a description; Lublin & Reingold, 1996). Approximately 85% of persons 
with MS have the relapsing-remitting subtype (RRMS). Researchers have suggested that 
relapsing-remitting MS (RRMS) and secondary-progressive MS (SPMS) are part of the 
same continuum of active disease progression (Ransohoff, 2000). In particular, 
Weinshenker and colleagues (1989a) found further evidence in this regard, as 50% of 
individuals with untreated RRMS advance to SPMS within 10 years, and 90% advance 
within 25 years. 
The hallmarks of RRMS are intermittent, acutely inflammatory neurological 
attacks (relapses) followed by periods of either partial or complete recovery (remissions) 
(Lublin & Reingold, 1996; Weinshenker et al., 1989b). Relapses occur unexpectedly and 
gradually (Phillips, 2004), typically lasting longer than 24 hours (Schumacher et al, 
1965). Over the course of a relapse, individuals may experience such symptoms as 
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blurred vision, pain, extreme fatigue, muscle spasticity or weakness, varying degrees of 
urine or fecal incontinence, ataxia, or cognitive impairment (Paty, 2000). A remission 
may occur over weeks to months (Phillips, 2004; The IFNB Multiple Sclerosis Study 
Group, 1993). 
The clinical course of RRMS is unpredictable and different for each individual, 
making diagnosis and treatment difficult.  Early in RRMS, the average rate of relapses is 
approximately one per year (range 0.1 to 1.0; Compston & Coles, 2002). As the disease 
progresses, the relapses may subside, and individuals may experience a slow but gradual 
decline (Confavreux et al., 2000; Lacey et al., 2000). In a study of 190 patients with 
RRMS, Amato and Ponziani (2000) found that residual disability post-relapse was a more 
important predictor of secondary progression (p<. 0001) than the number of relapses (in 
the first 2 years). Kurtzke developed the Expanded Disability Status Scale (EDSS) (1983) 
which is used widely to measure the progression of MS and to evaluate treatment efficacy 
(See Table 2).  Confavreux and colleagues (2000) used the EDSS to determine the 
timeline of progression from RRMS to SPMS, charting a median time of 15 years to use 
of a cane (EDSS 6), 20 years to wheelchair use (EDSS 7), and 25 years to full 
confinement to wheelchair or bed (EDSS 8). 
Pathophysiology of RRMS 
 The mechanism of neurological damage in RRMS is complex and not well 
understood. Some scientists purport that two main pathological processes, myelin sheath 
destruction and nerve fiber (axonal) damage, occur concomitantly (Smith & McDonald, 
1999). An unknown event triggers an autoimmune process of inflammation and 
demyelination of the myelin sheath in the brain and spinal column (Trapp et al., 1998). 
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The myelin sheath, a fatty, white, protective covering of the neurons, normally facilitates 
the transmission of nervous impulses. With demyelination, lesions or placques disrupt the 
surface of the myelin sheath, while inflammatory by-products damage the underlying 
axon (Comi, 2000; Ransohoff, 2000, Trapp et al., 1998). The nerve impulses become 
erratic, transient, and slowed, which may result in neurological signs or symptoms 
(Ransohoff, 2000; Trapp, Ransohoff, & Rudick, 1999). Subsequently, as the 
inflammation resolves and partial remyelination restores conduction, neurological 
symptoms tend to decrease or disappear (Smith & McDonald, 1999). This destructive 
process begins early in the disease and may be present without manifestation of clinical 
signs or symptoms (Comi, 2000; Coyle, 2003). 
 The relevance of axonal damage in the course of RRMS is not yet fully 
understood, and has been under debate.  Some researchers have suggested that axonal 
damage occurs as a result of the early and persistent inflammation in relapses (Miller, 
Grossman, Reingold, & McFarland, 1999; Ransohoff, 2000; Trapp, et al., 1998). The 
early subclinical axonal damage appears to continue even after the inflammation resolves 
(Confavreux et al., 2000; Komek & Lassman, 2000), and may result in brain atrophy 
(evident on MRI) (Ransohoff, 2000). However, Chaudhuri and Behan (2005) argued that 
the inflammatory event and axonal damage are unrelated, and have cast doubt on the 
efficacy of the current injectable DMD therapy. They proposed that the axonal damage 
causes degeneration that is not halted by the immunologic properties of the injectable 
DMDs. 
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Psychosocial impact of RRMS 
The average age of onset of RRMS is 30 (Confavreaux et al., 2000). Therefore, 
this disease can have financial, vocational, and social implications for young people 
during their most productive years. One survey of 246 individuals found that the greatest 
impact of RRMS was on reduction of income (37%), unemployment (40%), change in 
hobby (25%), social isolation (29%) and increased need for assistance (37%) (Gedizliogu 
et al., 2000). Moreover, 60% of the $20 billion annual cost related to MS in the United 
States (National Multiple Sclerosis Society, 2004a) is attributed to lost productivity and 
caregiving by the family (Grima et al., 2000; Miltenberger & Kobelt, 2002; Kobelt, et al, 
2006). 
The unpredictable nature of relapses, short-lived yet bothersome symptoms, and 
varying degrees of disability inherent in RRMS may cause individuals to make changes 
in their work habits (Smith & Arnett, 2005; Solari & Radice, 2001). Earlier studies 
indicated that approximately 70 to 80 per cent of individuals with MS stopped working 
within five years of diagnosis (O’Day, 1998). However, more recently, Smith and Arnett 
(2005) found that some individuals decide to continue to work, though in a lesser 
capacity. Johnson and colleagues (2004) suggested that a combination of personal, 
functional, and workplace limitations cause reduced employment for many patients with 
RRMS. For example, Smith and Arnett (2005) reported that 90% of workers cut back 
their work due to fatigue. Conversely, factors such as advanced education, desirable job, 
insurance needs, and mild symptoms may impact the decision to continue working part-
time. 
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Studies indicated that employment among individuals with MS decreases as the 
level of disability (EDSS) increases (Grima et al., 2000; Smith & Arnett, 2005). In one 
study, full time employment decreased from 51% at EDSS 1 to 5% at EDSS 6 
(Gedizlioglu et al, 2000). Absences caused by increasing disability or relapses may range 
from 73-87% (Grima et al., 2000). Other consequences of the disease include time lost 
from work (Gedizlioglu et al., 2000; Grima et al., 2000), job change or revision 
(Gedizlioglu et al., 2000), loss of social and professional contacts (Hakim, 2000), and 
early retirement (Grima et al., 2000; O’Day, 1998). The loss of employment and reduced 
or lost wages may result in a decreased quality of life for many patients and their families 
(Grima et al., 2000; McCabew & De Judicibus, 2005; Merkelbach, et al., 2002; Parkin, et 
al., 2000; Solari & Radice, 2001). 
Pope and colleagues (2002) found that health care utilization among insured 
individuals with MS (private insurance, Medicare, Medicaid) is two to three times higher 
than individuals without MS. Health care costs related to RRMS include increased use of 
health care commensurate with increased disability (increased EDSS) and intermittent 
relapses (Grima et al., 2000; Miltenburger & Kobelt, 2002; Phillips, 2004). The cost of a 
relapse can range from $248 for mild relapses to $12,870 for severe relapses (O’Brien, 
Ward, Patrick, & Caro, 2003). These factors, coupled with reduced or lost wages, can 
have an adverse financial effect on both the patient and their family. 
In summary, RRMS is a complex, unpredictable disease with an uncertain illness 
course. The transient nature of relapses and disability may adversely affect patients’ 
physical, vocational, and social wellbeing. Patients and families may face loss of 
employment and social contacts, increased health care costs, and a reduced quality of life. 
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Untreated, the disease may progress to almost total dependency for 90% of patients. 
However, scientists and researchers continue to make new discoveries regarding the 
disease, including treatments that alter the immune response (injectable DMDs). Early 
and sustained injectable DMD therapy may stabilize RRMS, delay progression, reduce 
healthcare costs and improve quality of life for patients (Flachenecker & Rieckmann, 
2003). 
 Injectable DMDs for RRMS 
Injectable DMDs are currently the standard platform therapy for RRMS.  
Developed in the mid-to-late 1990’s, this therapy includes interferon and non-interferon 
medications. Injectable interferons have been approved by the Food and Drug 
Administration (FDA) for their anti-inflammatory, immunomodulatory, and antiviral 
properties (Dhib-Jalbut, 2003; Kendrick & Johnson, 2000). The injectable interferons 
include Interferon beta-1b (IFNB-1b; Betaseron ©; Berlex Laboratories), Interferon beta-
1a intramuscular (IFNB-1a IM; Avonex ©; Biogen, Inc.), and Interferon beta-1a 
subcutaneous (IFNB-1a SC; Rebif ©; Serono, Inc.). Glatiramer acetate (GA; Copaxone 
©; Teva Neuroscience) is a non-interferon synthetic protein medication that blocks the 
autoimmune inflammatory mechanism in the brain (See Table 3 for a description of the 
injectable DMDs). 
Some uncertainty exists regarding the efficacy of the injectable DMDs. The 
results of the original two-year, phase III, randomized placebo-controlled clinical trials 
indicated that both the interferon (IFNB beta-1a IM, IfNB beta-1a SC,  IFNB beta-1b) 
and the non-interferon (glatiramer acetate) medications achieved several outcomes: 
reduction in the frequency of relapses by approximately 30% (Jacobs et al., 1996; 
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Johnson et al., 1995; The PRISMS Study Group, 1998; The IFNB Multiple Sclerosis 
Study Group, 1993), prolonged periods of remission (Johnson et al., 1995; The IFNB 
Multiple Sclerosis Study Group, 1993), reduction of disease activity, as seen on MRI 
(Jacobs et al., 1996; Johnson et al., 1995; PRISMS Study Group, 1998; Paty, Li, & The 
IFNB Multiple Sclerosis Study Group, 1993) and delayed progression of disease, as 
measured by  the EDSS (Jacobs et al., 1996; PRISMS Study Group, 1998).  (See Table 4 
for efficacy profiles of the immunomodulators). These findings were replicated in 
extended studies, including the IFNB Multiple Sclerosis Study Group & the Unversity of 
British Columbia MS/MRI Analysis Group (1995); Johnson et al., (1998); Johnson et al., 
(2000); The Prisms Study Group, and the University of British Columbia MS/MRI 
Analysis Group (2001); Panitch et al., (2002); Fernandez, et al., (2003); Onesti et al., 
(2003); Clanet, Kappos, Hartung, Hohlfield, and the European IFNB-1a Dose 
Comparison Study Investigators (2004); and Ford, et al., (2006). However, the validity of 
these findings has since been debated (Chaudhuri & Behan, 2005; Clanet & Cucherat, 
2003; Confavreux et al, 2000; Fillippini et al, 2000; Freedman, King, Oger, Sharief, & 
Hartung, 2003; Goodin, 2003; Kappos & Kesselring, 2003; Kolar, Baurie, & Lee, 2003; 
Paty, Arnason, Li, & Traboulsee, 2003; Rice et al., 2001; Rudick, Cookfair, Griffin, 
Hauser, & Plantadosi, 2003; Greenstein, 2001, 2002). A meta-analysis of the original 
clinical trials reported that the use of the injectable interferons demonstrated only one 
outcome: a reduction in the number of patients having relapses (Fillippini et al, 2003). 
Moreover, this outcome could not be projected beyond one year. The authors attributed 
their findings to flawed study designs in the original clinical trials. 
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The meta-analysis was challenged by many of the authors of the original clinical 
trials (Freedman, et al., 2003; Goodin, 2003; Kappos & Kesselring, 2003; Kolar, et al., 
2003; Paty, et al., 2003; Rudick, et al., 2003). As a result, a more comprehensive meta-
analysis was conducted by Rice and colleagues (2001), which found that, in addition to 
the reduced number of patients with relapses, there was also a reduction in the number of 
participants whose MS had progressed at the end of two years of treatment with 
interferons (versus patients not on treatment). Munari, Lovati, and Boiko (2004) 
conducted a similar meta-analysis on the non-interferon, glatiramer acetate, and found a 
lack of any significant benefits of the medication. More recently, Chaudhuri & Behan 
(2005) argued that MS is a neurodegenerative, rather than an inflammatory disease; they 
suggested that the anti-inflammatory properties of the injectable DMDs are ineffective in 
addressing disease progression. 
In summary, current findings suggest that the interferons have a modest benefit in 
reducing  relapses and delaying short-term progression, but long-term efficacy is 
uncertain (Confavreux et al., 2000). Yet, despite their limited benefits, the injectable 
DMDs have increased optimism and improved quality of life for many patients with 
RRMS. Given the early, subclinical, and potentially irreversible neurological damage in 
RRMS, scientists and clinicians have strongly advocated for injectable DMDs as the most 
appropriate initial treatment option for all patients diagnosed with RRMS (Comi, 2000; 
Coyle & Hartung, 2002; Freedman et al., 2002). A consensus statement published by the 
Medical Advisory Board of the National Multiple Sclerosis Society recommends 
immediate and prolonged treatment for newly diagnosed cases of RRMS (See Table 5; 
National Multiple Sclerosis Society, 2005). 
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Patient response to disease and treatment 
Patients with RRMS report a lower quality of life compared to patients with other 
diseases, as well as the general population. In one study, patients scored lower on every 
domain in the Medical Outcomes Study Short Form-36 scale (MOS SF-36) compared to 
patients with Parkinson’s disease and healthy controls (except for mental health; Riazi et 
al., 2003).  The MOS-SF 36 is a 36-item self-report instrument that measures patients’ 
health status across 8 domains: physical functioning, role-physical, bodily pain, general 
health, vitality (energy and fatigue), social function, role-emotional, and mental health 
(Ware & Shelbourne, 1992). Increasing disability was associated with lower scores on the 
MOS-SF36 in another study (Prosser, Kuntz, Bar-Or, & Weinstein, 2003). However, a 
lower quality of life may also be reported by patients with milder impairments (Ford, 
Gerry, Johnson, & Tennant, 2001). Hemmet, Holmes, Barnes, and Russell (2004) found 
that patients experiencing a relapse were more likely to report a lower quality of life. 
McCabe and McKern (2002) found lower subjective and objective measures of all 
domains of the World Health Organization Quality of Life-100 scale (WHOQOL-100) 
among patients with RRMS than among the general population.  Factors that predict 
quality of life among patients with RRMS include physical disability, disease 
progression, fatigue, cognition, and depression (Benedict et al., 2005). 
Several studies have examined quality of life among patients with RRMS who are 
undergoing injectable DMD treatment (Arnoldus, et al., 2000; Gottberg, Gardulf, & 
Fredrikson, 2000; Hemmet et al., 2004; Isaksson, Ahlstrom, & Gunnarsson, 2005; Lily et 
al., 2006; Zivadinov et al., 2003). Hemmet and colleagues (2004) found that mean scores 
on 7 of the 8 domains of the SF-36 were significantly higher among patients (N = 131) 
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who were undergoing beta interferon therapy (type not specified) than among patients (N 
= 1554) who were not on the therapy (p = <.05; physical functioning domain was p = 
.061). Conversely, Isaksson and colleagues (2005) found no significant difference in 
MOS SF-36 scores between treated patients. 
In spite of their benefits, side effects of the injectable DMDs can affect quality of 
life for many patients. Arnoldus and colleagues (2000) found a significant increase in one 
of eight domains (role-functioning scores) on the MOS SF-36 among patients with 
RRMS during the first six months of treatment with IFNB-1b (p < .001). However, 
patients who reported more side effects were more likely to have lower scores on several 
subscales, including role-functioning scores, than those who reported fewer side effects. 
In another study of IFNB-1a (IM) (n = 17) and IFNB-1b (n = 23), two side effects, 
asthenia and fatigue, were associated with a lower quality of life (Gottberg et al., 2000). 
Other studies found no association between self-reported side effects and quality of life 
during a year of treatment with IFNB-1a (IM) (Vermersch, de Seze, Delisse, Lemaire, & 
Stojkovic, 2002; Zivadinov et al, 2003). 
McGuiness and colleagues (2001) conducted a pilot study among 63 participants 
who were using either injectable interferons (IFNB-1a, IFNB-1b, or IFNB-1a SC, not 
specified) or glatiramer acetate. The study measured participants’ self-report of post-
injection perceived wellness. Those patients using an injectable interferon were 5 times 
more likely to feel unwell 12-16 hours post injection than the patients who used 
glatiramer acetate (McGuiness, Lagendyk, Halle, Jacques, & Metz, 2001). Moreover, 
participants were nearly twice as likely to alter their daily activities because of the side 
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effects. No details were provided regarding the type or dose of medication, or specific 
side effects. 
In summary, many patients with RRMS report a lower quality of life concerning 
their physical, cognitive and psychological function. In contrast, patients who are 
undergoing DMD treatment report an improved quality of life. However, treatment side 
effects may result in reports of reduced quality of life and disruption in daily living. 
These factors may influence patients’ attitudes and behavior regarding their injectable 
DMD therapy. 
Literature Review 
Management of the Injectable DMD 
In chronic illnesses such as RRMS, effective disease management may be as 
critical to patients’ wellbeing as their access to health care (Horne, 2003). People with 
RRMS must somehow incorporate the disease into their lives. In so doing, they must 
develop a regimen of day-to-day management that includes health care visits and 
treatment regimens. On average, patients with chronic illness see their health care 
provider one hour per year, spread over four visits (Kaptein et al., 2003). Therefore, for 
the most part, patients manage their day-to-day illness on their own. 
Patients with chronic illnesses are taking a more active role in treatment planning 
(Bodenheimer, Lorig, Holman, & Grumbach, 2002; Heesen, Kasper, Segal, Kopke, & 
Mulhauser, 2004; Nicholl, 2002). This includes deciding whether, when, and how to 
engage in their therapy. With regard to RRMS, researchers have advocated for immediate 
and long-term injectable DMD therapy to reduce relapses, delay progression, and 
improve quality of life. Yet, it is unclear why some patients have successfully initiated 
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and continued injectable DMD, while others have delayed, interrupted, or discontinued 
treatment. Many factors influence effective day-to-day management of RRMS with 
DMDs (Johnson et al., 2006; Nicholl, 2002). Among the most common factors are 
adherence behaviors, medication adverse effects, financial constraints, injection issues, 
treatment beliefs, and health care provider influence. Some of these factors may be 
unnecessary barriers that prohibit effective day-to-day management of the injectable 
DMDs. 
Initiation and Adherence to Injectable DMDs 
Recent surveys have revealed that, despite the current treatment 
recommendations, an estimated one-third to two-thirds of all eligible individuals with 
RRMS are not using DMDs (Anasarala et al., 2007; Lo, et al., 2005; Miller, Crayton, & 
Namey, 2004; Taylor & Leitman, 2001). A Harris Interactive Poll conducted in 2001 
indicated that 42% of patients with MS were not undergoing the recommended injectable 
DMD therapy; furthermore, those persons who were 5 years (or longer) from diagnosis 
were even less likely to be taking the medications (Taylor & Leitman, 2001). However, 
this could be due to the fact that most of the DMDs were approved for use in the mid-to-
late 1990’s. Forty-three per cent of those surveyed responded that they were not on the 
therapy because they were not experiencing active MS disease symptoms. Conversely, 
Rio and colleagues (2005) found that patients with RRMS who discontinued interferon 
therapy were young, female, and more disabled than their counterparts at initiation of 
treatment (p = <.0001). A more recent study suggested that non-usage may be as high at 
62% among patients treated by a neurologist, and 92% by patients seen by family 
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practitioners or internists (Anasarala et al., 2007). There was no indication of the reason 
for non-usage in the study. 
Other reported reasons for not being on the medication have been related to 
medication effects, patients’ beliefs, cost, and health care provider influence. Daugherty 
and colleagues (2005) found that discontinuation of injectable DMDs was based on 
adverse effects, disease progression, perceived lack or efficacy, and cost.  Similarly, 
Johnson and colleagues reported that patients with RRMS stopped injectable DMD 
therapy due to concerns regarding side effects, feeling well, fear of needles, cost, and 
physician recommendation (Johnson, et al., 2006). In both studies, type of injectable 
DMD was not a factor. 
Length of time on therapy appears to influence adherence. A review of 
pharmaceutical records of over 21,000 patients who were using injectable DMDs from 
January 2000 to March 2002 revealed that adherence initially was 68-76% (PharMetrics 
Patient Centric Database, 2000-2002, data on file). After 2 years on therapy, however, the 
number of patients continuing the medication decreased by as much as 18%, depending 
on the injectable DMD. Similarly, Ruggeri and colleagues (2003) found that 
approximately 50% of nonadherent patients discontinued treatment within the first two 
years. Munschauer and Tyry (2004) found that 6-11% of patients (n = 6211) discontinued 
injectable DMDs within 6 months of initiation. 
Tremlett and Oger (2003) conducted a retrospective chart review of 846 patients 
who received injectable DMDs over 29 months. One third of the patients stopped 
treatment for at least one month, and 13 % switched to another treatment.  Perceived lack 
of efficacy, the main reason for stopping or switching, was significantly related to the 
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type of therapy (p = <.05). In another study, particular injectable DMDs were reported to 
be more problematic than others; for example, of patients who stopped treatment due to 
perceived progression, 35% were on IFNB-1a IM (Avonex ©), 25% were on glatiramer 
acetate (Copaxone ©), and 21% were taking IFNB-1b (Betaseron ©) (NARCOMS News, 
1999). Ruggieri and colleagues (2003) also found that discontinuation was varied 
depending on the injectable DMD used. 
Several quantitative studies have examined factors that influence adherence to the 
DMDs. Fraser and colleagues (2001) identified predictors of adherence among patients 
with RRMS undergoing treatment with glatiramer acetate (n = 274), and those who 
discontinued treatment (n = 116). Findings indicated that hope (p = < .05), self-efficacy 
(p = < .01), no prior use of immunomodulators (p = < .03), and perception of physician 
support (p = < .05) positively influenced adherence. Other studies found that pre-
treatment expectations, post-injection anxiety (Mohr, Boudewyn, Likosky, Levine, & 
Goodkin, 2001) and depression (Mohr et al., 2000) negatively affected adherence. 
In summary, despite positive (albeit limited) documented effects of injectable 
DMDs, one-third to two-thirds of all patients with RRMS are not receiving therapy. 
Some patients never begin therapy; other patients discontinue treatment up to 2 years 
after initiation. Still others switch therapies. The most common reasons for non-initiation, 
switching, or discontinuing treatment are side effects, perceived lack of active disease 
symptoms, perceived lack of efficacy, perceived disease progression, and health care 
provider recommendation. 
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Medication Side effects  
Side effects related to injectable DMDs, including flu-like symptoms and 
injection site reactions, are common among patients with RRMS. For example, 
approximately 3 to 6 hours after injection, up to 75% of  patients initially experience a 
constellation of flu-like symptoms, including headache, fever, myalgia, fatigue, and chills 
(Walther and Hohlfield, 1999). These effects are mild, and typically subside within 24 
hours, but may persist for several weeks (Gottberg et al., 2000). In the original clinical 
trials, 48% of the participants reported flu-like symptoms, which disappeared after three 
months (The IFNB MS Study Group, 1993; Jacobs et al., 1996; The PRISMS Study 
Group, 1998).  The incidence of localized skin injection reactions, including pain, 
erythema, and swelling, can be as high as 90% (Frohman et al., 2004). 
The frequency and nature of adverse effects may vary among the injectable 
DMDs (Gottberg et al., 2000). IFNB-1b SC (Betaseron ©) may cause more intense 
reactions than the other interferons (Trojano et al., 2003), while side effects related to 
IFNB-1a IM (Avonex ©) may be more long-lasting (Zivadinov et al., 2003). Side effects 
can cause premature discontinuance or switching of the injectable DMDs (Daugherty, et 
al., 2005; O’Rourke & Hutchinson, 2003).  Side effects most frequently cited are flu-like 
symptoms, headache, fatigue, injection site reactions, and depression (Tremlett & Oger, 
2003).  (See Table 3 for common side effects). 
Other neurological effects related to the injectable DMDs, such as increased 
spasticity (hypertonia), asthenia, and increased fatigue, may mimic symptoms associated 
with MS, and their persistence may be confused with relapse or worsening disease 
(Gottberg et al, 2000, Walther & Hohlfield, 1999; Zivadinov et al., 2003). Hypertonia is 
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listed as a common side effect with both IFNB-1a IM (data on file, Biogen, 2003), and 
IFNB-1b SC (data on file, Serono, 2004), and has been attributed to the discontinuation 
or modification of IFNB-1b SC therapy. 
Cost of Injectable DMD 
The financial aspect of illness management with the injectable DMDs can be an 
overwhelming problem when initiating or continuing treatment. In a survey of 562 
individuals with RRMS who were not receiving treatment, 33% indicated that cost was 
an obstacle (Taylor & Leitman, 2001). An earlier survey by NARCOMS News (1999) of 
over 400 individuals with RRMS also found that cost was the third most common reason 
for discontinuing treatment. 
The annual wholesale cost of the injectable DMDs ranges from $16,000 to over 
$20,000 (National Multiple Sclerosis Society, 2005). Therefore, the actual cost to the 
patient will be even higher. Some state and federal programs assist uninsured and 
impoverished individuals, but the main burden of cost is undertaken by the patient and 
family. The coverage of treatment costs by insurance companies is variable and may be 
restrictive. According to National Multiple Sclerosis Society statistics (2002a), 60%-65% 
of individuals have private insurance, 20%-25% have Medicare, 5%-10% have Medicaid, 
and 5%-10% are uninsured. Many private insurance companies provide at least partial 
coverage, but may impose strict limitations on the type and extent of treatment. As of 
2006, Medicare (Part D) covers approximately 70% of costs of the medication (Jacobs 
Neurological Institute, 2007). Medicaid also imposes conditions on the type of 
medication, as well as eligibility for treatment coverage. 
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Still, the personal expense for injectable DMD treatment is considerable. For 
example, under the anticipated Medicare prescription benefits, a person whose income is 
more than $14,500 (for a married couple, the income is $19,500), can expect to pay 
approximately $5,000 out of pocket annually for an average treatment cost (per injectable 
DMD) of $20,000 (Simons & King, 2004). This does not take into account other 
medications that may be needed (for example, antispasmodics, incontinence medications, 
etc.) or other health care costs. Given the proportion of individuals who reduce their work 
schedules or retire early, the cost of treatment may be prohibitive. A survey of over 
25,000 individuals over age 18 with disabilities found that uninsured adults were four 
times more likely to be noncompliant because of cost than those with insurance (Kennedy 
& Erb, 2002). 
Injection Issues 
The DMDs are currently only available in the injectable form to patients with 
RRMS. Approximately half of all individuals are expected to have injection problems 
(Mohr et. al., 2001). Medication taking requires patients to learn new skills (Russell, 
Conn, & Ashbaugh, 2003). Complex preparation and administration using a syringe, as 
well as painful skin reactions, can be a problem for many patients (Harris et al., 
2005/2006; Nicholl, 2002). Some patients are unable to self-inject because of loss of 
sensation, weakness in their hands and fingers (Holland et al, 2001), poor hand-eye 
coordination, and tremor (Munschauer & Weinstock-Guttman, 2000). Others experience 
pre-injection anxiety (Cox & Stone, 2006). A study of 101 patients with RRMS found 
that 12 % had discontinued treatment in the first six months (Mohr et al., 2001). 
Treatment discontinuation was significantly related to pre- injection self-efficacy 
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expectations (p = < .0001), post-injection anxiety (p = < .05), and injection administrator 
(p = < .0001). Patients who required someone else to administer the injection 
discontinued the treatment within 6 months.  
Medication Beliefs 
Beliefs about medications can influence an individual’s attitudes and behavior 
concerning injectable DMDs. Individuals who are faced with the prospect of long-term 
medication use must weigh the perceived benefits of the therapy against their concerns, 
which may include medication side effects, disruptions, uncertain efficacy, and financial 
constraints (Horne, 1999). Perceived benefits and concerns are unique to each patient in 
their individual life circumstances. Depending on their beliefs, patients may either initiate 
and continue their medication regimen, or become intentionally non-adherent (Wroe, 
2001). 
In a phenomenological study conducted by Miller and Jezewski (2001), patients 
with RRMS reported experiencing a sense of being ‘proactive’ in undergoing treatment 
with injectable beta interferon-1a IM. However, other research suggested that patients 
who are not experiencing MS symptoms are less likely to be on DMDs (Johnson et al., 
2006; Miller, et al., 2004; Taylor & Leitman, 2001). In a survey of 562 patients with 
RRMS, 87% believed that the main objective of therapy should be to slow progression 
rather than reduce relapses (Taylor & Leitman, 2001). Yet, patients who are not 
undergoing therapy may be unaware that the damage and disease are ongoing, even when 
there are no obvious signs or symptoms (Jewell, 2001). Their beliefs may cause them to 
delay, or even decline, therapy at a time when it would be most beneficial. 
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Breakthrough symptoms or worsening disease can occur in some patients despite 
taking injectable DMDs. The clinical indicators of worsening disease include relapses, 
new or worsening symptoms, change in cognition, and new lesions (on MRI; Bashir et al, 
2002). Many factors can contribute to worsening disease, including infections, 
neutralizing antibodies, treatment inefficacy, or an unknown etiology (Miller et al, 2004).  
Generally, an infection (e.g., urinary, respiratory) can cause a ‘pseudo’ relapse, and 
resolving it will usually mitigate the exacerbation (Confavreux, 2002). On the other hand, 
neutralizing antibodies, the immune system’s reaction to the injectable interferons, cannot 
be eradicated, and their presence appears to reduce the efficacy of the interferon (Rice, 
2003). Neutralizing antibodies may appear as late as 18 months after the start of therapy, 
and can occur in any patient (Miller et al, 2004). This may be one of the reasons for 
delayed switching or discontinuing medication. 
In light of the insidious neurological damage in RRMS, random occurrence of 
neutralizing antibodies, and uncertain efficacy of the injectable DMDs, a panel of experts 
has recently developed a model for identification and aggressive treatment of disease 
progression (Bashir et al, 2003). Many researchers are now advocating the use of 
combination therapy, such as steroids, additional DMDs, or other medications in 
situations of clinically identified worsening disease (Jeffery, 2004; Stuart & Vermersch, 
2004). However, patients may be reluctant to add to their medication regimen, and may, 
instead, decide to discontinue treatment. 
Several studies reported an association between perceived lack of efficacy and the 
discontinuation or switching of therapy (Onesti et al, 2003; O’Rourke & Hutchinson, 
2005; Rio et al, 2005; Ruggieri et al., 2003; Tremlett & Oger, 2003). In a retrospective 
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chart review, perceived lack of efficacy was the primary factor related to early 
discontinuance of beta interferon-1a treatment (Tremlett and Oger, 2003). On the other 
hand, O’Rourke and Hutchinson (2005) found that patients who discontinued therapy due 
to treatment failure had continued treatment over one year longer than patients who 
discontinued treatment due to adverse effects. Thus, in spite of adverse effects, some 
patients’ beliefs about injectable DMDs will motivate them to continue treatment. 
A pilot study examining patients’ (with RRMS) concerns (N = 63) prior to 
beginning injectable DMD treatment found that 86% were concerned about the treatment 
efficacy; however, 81% were also concerned about side effects. Patients’ concerns can 
influence discontinuation of the treatment, especially if obvious symptoms validate their 
concerns (Lagendyk, et al., 2001). However, patients may mistake side effects from 
interferon therapy as worsening symptoms (Calabresi, 2002). Therefore, they may 
discontinue their treatment before identifying the cause or investigating other treatment 
options. 
In summary, beliefs about medications may influence initiation and continuing of 
treatment. Perceived lack of efficacy or worsening disease can cause patients to 
discontinue or switch, even without knowing the cause. Conversely, lack of obvious 
symptoms may cause patients to doubt active disease and, therefore, delay treatment. 
Patients may have unrealistic expectations about the injectable DMD treatment. 
Developing a clear understanding of patients’ specific beliefs will help health care 
providers to educate, counsel and support patients regarding injectable DMD treatment. 
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Health Care Provider Influence 
Little is known about the influence health care providers may have on their 
patients’ knowledge and experiences associated with the use of DMDs. Approximately 
half (57%) of patients with multiple sclerosis are treated by an MS specialist; the 
remainder is under the care of a general neurologist or primary care provider (Vickery, et 
al., 1999). Vickery and colleagues (1999) found that patients who are treated by MS 
specialists are more likely to be using DMDs and less likely to discontinue treatment (p = 
< .05). His findings were consistent with those of Anasarala and colleagues, who found 
that up to 92% of patients seen by family practitioners or internists were not on treatment. 
He also found that 62% of patients seen by neurologists were not on treatment. On the 
other hand, one study revealed that more than 60% of patients who had stopped their 
therapy were following their health care provider’s directive (Hadjimichael & Vollmer, 
1999). However, in that study, no distinction was made of the type of health care provider 
(i.e., neurologist, MS specialist, etc.). 
Management of RRMS has improved since DMDs were introduced in the mid-
1990’s. Injectable DMDs have achieved several outcomes, including reduction of 
relapses by 30%, a reduction in active disease, and a delay of progression in the short-
term. Studies have suggested that patients who delay DMD use are at higher risk for 
relapses (p = < .0001) and disease progression (p = < .03) than patients who started 
therapy immediately after diagnosis (Johnson et al., 2003). In addition, studies have 
indicated worsening disease among patients who have discontinued injectable DMDs 
(Milanese et al., 2003; Rio et al., 2005). A consensus statement regarding treatment for 
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RRMS has recommended implementing immediate and sustained injectable DMD 
therapy to take full advantage of the medication’s benefits. 
Like their patients, eighty-one percent of health care providers perceive the main 
objective of injectable DMD therapy is to delay progression (Taylor & Leitman, 2001). 
However, many health care providers may believe their patients are experiencing a 
benign course, and therefore may advise delaying treatment (Holland et al., 2001; Pittock 
et al., 2006). A 20-year follow-up study by Pittock and colleagues (2004) found that 
patients with minimal disability (EDSS of 2 or less) 10 or more years after diagnosis have 
a 90% chance of remaining stable. This finding, which affects approximately one in five 
patients, may have implications for decision-making among health care providers and 
patients. Patients may decide to delay treatment, deciding, with their health care 
providers, to take a ‘watch and wait’ approach (Pittock et al., 2004; Pittock et al.,2006). 
The decision to delay treatment has been challenged by other researchers, who 
argued that the predictive certainty of the disease course is low in the first 5 years 
(Frohman, et al., 2006; Roach, 2006). They further asserted that injectable DMDs are 
largely ineffective in the progressive phase of MS. They suggested that an evaluation of 
MS stability using only the EDSS is not sufficient. A more multidimensional assessment 
should be included to determine disease impact, including quality of life, loss of 
employment, cognitive impairment, and mood disturbance. 
Given the uncertain and unpredictable course of RRMS, health care provider 
influence may be an important factor in patients’ experiences with management of 
injectable DMDs (Thorne, Con, McGuinness, McPherson, & Harris, 2004).  Fraser and 
colleagues (2001) reported that health care provider support was a predictor of adherence 
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to injectable DMDs among patients with RRMS (p = <.05). Yet, no description of the 
type of support was available from the study. Moreover, little information is available 
about the patient-provider decision-making process concerning initiating or continuing 
injectable DMD treatment. Zwibel (2003) found that, in the decision-making process 
concerning initiation of injectable DMDs, patients with RRMS and their physicians 
collaborated only 56% of the time, while patients alone made decisions 40% of the time. 
Moreover, some patients terminate their injectable DMD therapy between health care 
visits without informing their health care provider (Stickel, 2005). Patients and health 
care providers may have different perspectives on beliefs, concerns, adherence, and 
quality of life issues related to the treatment. Insight into patients’ daily experiences, 
including perceived barriers to treatment, beliefs, and concerns, may aid health care 
providers in providing appropriate support for day-to-day management. 
 Nurses are important participants in the team of health professionals that provides 
comprehensive care for patients with RRMS. Nurses may coordinate education, 
counseling, and support services for these patients. Many nursing organizations have 
derived guidelines and consensus documents regarding medication management and 
adherence issues related to DMD (Costello, Halper, Harris, & Kennedy, 2003; Denis et 
al., 2004; Holland et al., 2001a, 2001b). While these recommendations are based on 
quantitative studies and clinical anecdotes, the unique perspective of the patient with 
RRMS is largely absent. A qualitative description of the patients’ experience will provide 
important insights into the factors that influence effective management of injectable 
DMDs. That information will allow nurses and other health care providers to construct 
interventions that target these factors and improve management of the injectable DMDs. 
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Chapter II 
Conceptual Framework 
The organizing framework, Beliefs About Medicines (Horne, 1997), guided this 
qualitative study of the experience of managing RRMS among users and nonusers of 
injectable DMDs (see Figure 1). The framework purports that people’s adherence 
behaviors concerning medications are influenced by their beliefs. Individuals’ beliefs 
arise from their experience (current and prior) with medications or their interpretation of 
acquired information. According to the Beliefs About Medicines framework, patients 
participate in a continual process of weighing perceived needs for the medication (e.g, to 
improve or maintain health) against concerns regarding the medication’s effect on day-to-
day living (Horne & Weinman, 2002). The appraisal process is continuous, and the 
outcome (adherence behavior) may change depending on changing beliefs. 
Effective medication management requires ability and motivation (Horne, 2003). 
People’s ability to take medications may be affected by obstacles such as inconvenience, 
disruption, finances, lack of understanding, forgetfulness, or physical impairment. Yet, 
despite perceived barriers, many patients are adherent to their medication regimen. Prior 
medication adherence studies focused on the patients’ abilities to take medications, for 
example, comprehending, following directions, and remembering to take medications 
(Haynes, McKibbon, & Kanani, 1996; Horne, 1998; Wroe, 2001). However, little is 
understood about the role of motivation in adherence to medication regimens. 
Understanding what motivates individuals to begin a difficult medication regimen may 
help health care providers to better counsel, educate and support their patients (Horne, 
1999). 
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Development of the Framework 
The Beliefs About Medicines framework is congruent with social cognitive 
models (SCM), whose focus is on health-related behaviors. Two SCMs in particular, the 
Health Belief Model (HBM) (Rosenstock, 1974), and the Theory of Reasoned Action 
(TRA) (Ajzen & Fishbein, 1980), have been used to explain preventive health and 
adherence to medications. These models attempt to predict individuals’ health-related 
behaviors in terms of their beliefs, expectations, and values. For instance, the Health 
Belief Model suggests that patients evaluate their medication regimen based on several 
factors: the perceived threat of the illness and its consequences, the value that they place 
on the treatment, and their expected outcomes. The Theory of Reasoned Action proposes 
that intention and attitude (based on beliefs, normative values, and expectations) are 
predictive of adherence. 
The Beliefs About Medicines framework differs from these models in several 
ways. First, the Beliefs About Medicines framework evaluates not only the process of 
forming beliefs, but also examines the content of those beliefs (Horne, 2003).  Second, 
the Beliefs About Medicines framework suggests that health beliefs and behaviors are 
formed by continual appraisal of the medication and adherence outcomes. The Health 
Belief Model and Theory of Reasoned action purport that adherence is the result of a 
single decision. Moreover, the Theory of Reasoned Action is generally applied in 
circumstances where the patient believes they have control over the situation. Medication 
taking is often prescribed in circumstances that are out of patients’ control. Finally, the 
Health Belief Model and Theory of Reasoned Action assert that health behavior is driven 
by external motivation (e.g., health care providers, normative beliefs), while the Beliefs 
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About Medicines framework explores patients’ internal motivations (beliefs). The 
dynamic interaction of appraisal, belief formations, and adherence behaviors related to 
medications makes the Beliefs About Medicines framework the most appropriate 
organizing framework for this qualitative descriptive study. 
Conceptual Meanings 
The Beliefs About Medicines framework is composed of five constructs: General-
Harm, General-Overuse, Treatment Necessity, Perceived Concerns and Necessity-
Concerns Differential. General Harm and General-Overuse refer to patients’ perceptions 
about medicines in general. In order to focus on beliefs about particular medicines, only 
the related constructs, Treatment Necessity, Perceived Concerns and Necessity-Concerns 
Differential, will be explained in this study (See Table 7). 
Assumptions of the Beliefs About Medications Theory 
1) Patients’ adherence to their medication regimen are influenced by their beliefs 
about the medicine. 
2) Patients generate a set of beliefs about their prescribed medicine, including 
perceived treatment necessity and specific concerns; a predominance of one set of 
beliefs over the other determines adherence behaviors. 
3) Patients’ treatment beliefs are influenced by beliefs they hold about their illness, 
information or experiences related to the prescribed medicine, and perceptions of 
personal identity and control. 
4) Patients maintain a constant appraisal of their adherence behavior concerning 
their medication regimen; the appraisal may lead to a reinforcement or change in 
treatment beliefs. 
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Characteristics of the Beliefs About Medicines Framework 
Treatment Necessity 
Treatment necessity is the belief that a particular medication is essential for 
treatment. Perceived need is individual and may be influenced by several factors, 
including beliefs about medicines in general, prior experience with the medication, illness 
beliefs, filtered information, and social or cultural expectations (Carder, Vuckovic, & 
Green, 2003). Beliefs about the medication concern its identity, cause, timeline, 
cure/controllability, and consequences (Horne et al, 2003). Information about the 
medication may be acquired from various sources, including the social network, written 
materials, online resources, or health care providers. Perceived need can change 
according to changing information, experiences, or beliefs. 
Perceived treatment necessity is related to patients’ perceptions of their illness 
(Horne & Weinman, 2002; Vaughan, Morrison, & Miller, 2003). Initially, many patients 
assess their illness to determine whether it warrants treatment (medication). Patients may 
view their illness as temporary, and believe they can ‘ride out’ their condition without 
medication. The onset, duration, and intensity of the condition can also influence their 
decision. For instance, acute, persistent, or bothersome symptoms may provoke the desire 
for palliative or prophylactic medication; conversely, unpredictable, sporadic, or mild 
symptoms may convince patients that the illness is benign and doesn’t require medication 
(Horne et al, 2001b). The long-term consequences of the illness may influence patients’ 
decisions to start a medication regimen. Patients may fear the long term prognosis of 
disability, and see the medication as a way to ward off problems. For example, people 
who believed that asthma would last a long time with severe consequences had stronger 
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beliefs in the necessity of their prescribed medication and reported lower personal 
nonadherence (Horne & Weinman, 2002). 
Perceived treatment necessity is also related to the person’s sense of identity and 
control. After diagnosis, many patients want to maintain their sense of the ‘old self’, even 
as they redefine themselves as medication takers (Carder et al., 2003). For asymptomatic 
patients, taking the medication may be the only sign of the disease. They may decline 
medication because of the fear that they may become different. However, the need to take 
medication may also signify the need for self-efficacy or control over the disease. Other 
patients perceive themselves to be immune to illness. A study of 100 HIV-positive 
patients found that perceptions of imperviousness to disease were related to refusal of 
antiretroviral medications (Cooper et al, 2002). 
Specific concerns 
Patients’ perceived needs concerning their medication are countered by their 
concerns regarding its negative effects. Specific concerns are anticipations of unpleasant 
adverse effects or disruption by a particular medication. Concerns may develop from 
concrete experiences with the medication (i.e., adverse effects, disruption). Concerns may 
also be based on misinformation or miscommunication between the health care provider 
and patient (Horne, 1997). Other worries include the long term effects of the medication 
on the body. This set of concerns is universal across medication regimens. 
Concerns about adverse effects, disruption, or lack of efficacy may cause patients 
to delay or discontinue their medication regimen. For example, new or worsening 
symptoms may signify lack of efficacy (Jopson & Ross-Morris, 2003). Therefore, 
patients may decide to “take a chance” and forgo treatment rather than utilize a 
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medication that they perceive is ineffective, inconvenient, and unpleasant. For some 
patients, non-adherence could be a deliberate attempt to avoid or minimize harmful 
effects; for other patients, doubts about medication efficacy may cause them to forget to 
take their dose. (Horne, 2003). 
Necessity-concern differential 
The necessity-concern differential is described as a balance between perceived 
need and specific concerns about a medication. When initiating or continuing a 
medication, many patients conduct a general “cost-benefit” appraisal, along with an 
examination of their personal beliefs and expectations. This cost-benefit assessment may 
vary both among and within individuals at different times. In general, however, the 
necessity-concern differential may predict patients’ attitudes and behaviors (adherence) 
toward the medication. Strong perceptions of personal need may override concerns about 
the adverse effects (Horne, 1997). On the other hand, moderate levels of concern might 
stimulate avoidance of the medication, if necessity beliefs are low. This is particularly 
true if the person has little manifestation of the illness, and the adverse effects of the 
medication are disruptive and bothersome. In some studies, lower adherence was 
associated with a higher level of concern (versus perceived need) (Horne, 1997). In 
contrast, treatment necessity that outweighed specific concerns was related to greater 
adherence. Patients may also be partially adherent in some circumstances (Carder et al, 
2003).  
Use of the Theory in Research 
The Beliefs About Medicines framework has been used to study adherence in 
patients with asthma (Chambers, Markson, Diamond, Lasch, & Berger, 1999; Horne & 
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Weinman, 2002), chronic illnesses (Horne & Weinman, 1999), hemophilia (Llewellyn, 
Miners, Lee, Harrington, & Weinman, 2003), HIV/AIDS ( Horne et al, 2004; Horne, 
Cooper, Fisher, & Buick, 2001a ; Walsh, Horne, Dalton, Burgess, & Gazzard, 2001), 
hypertension (Ross, Walker, & MacLeod, 2004), kidney disease ( Butler, et al., 2004; 
Horne et al., 2001b), and rheumatoid arthritis (Neame & Hammond, 2005). The findings 
from these studies suggested a relationship between adherence and medication beliefs. 
Moreover, in one study, medication beliefs (r = 0.36; p = < .01) were stronger predictors 
of reported adherence than clinical or demographic variables (Horne & Weinman, 2002). 
The instrument, Beliefs About Medicines Questionnaire (Horne, Weinman, & Hankins, 
1999), was developed to quantitatively measure the constructs of the theory and their 
relationship to adherence. 
The Beliefs About Medicines framework has not been used among patients with 
RRMS nor with patients using injectable DMDs. Given the nonadherent rate concerning 
injectable DMDs among patients with RRMS, it is important to gain insight into factors 
that influence adherence behaviors. The Beliefs About Medicines framework may 
provide salient information about patients’ beliefs, concerns, and overall motivations 
concerning the injectable DMDs. 
Relevance to This Study  
 Patients with RRMS live daily with an unpredictable illness comprising transient 
symptomatology and an uncertain prognosis. Furthermore, many patients must make 
decisions about initiating or continuing injectable DMD that have a 30% short-term 
efficacy, unclear long-term benefits, and unpleasant side effects. The Beliefs About 
Medicines Framework may provide important insights regarding the medication beliefs 
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held by patients and how they influence adherence behaviors. Specifically, the constructs 
within this framework will help to address the following questions: 
• How do patients form their personal beliefs about the necessity of the 
injectable DMD? 
• How do necessity beliefs and perceived concerns determine adherence to 
the injectable DMD? 
• How do intentional adherence or nonadherence (based on medication 
beliefs) to the injectable DMDs influence the subjective experience of 
patients with the management of RRMS? 
The answers to these questions will help health care providers and researchers understand 
the experience of managing  RRMS  among adult women who are using injectable 
DMDs, have never used injectable DMDs, and have discontinued using injectable DMDs. 
An understanding of the experiences may lead to interventions involving support, 
counseling, and education that may ultimately improve patients’ management of RRMS. 
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Chapter III 
Methods 
Introduction 
This study used a qualitative descriptive approach to describe the experience of 
women as they managed RRMS. Patients with RRMS who are currently taking injectable 
DMDs, as well as those who have never initiated treatment and those who have stopped 
treatment, were interviewed about their experiences. Moreover, in concordance with the 
organizing framework, Beliefs About Medicines, the impact of patients’ treatment beliefs 
on their use or nonuse of injectable DMDs were examined (See organizing framework, 
Figure 1). Finally, the influence of health care providers on patients’ treatment beliefs 
and management of injectable DMDs were explored. Demographic (e.g., age, gender, 
marital status) and clinical data (length of time with RRMS, use of injectable DMD 
treatment, length of time on treatment, self-reported adherence to treatment) were 
collected from each participant. The Beliefs About Medicines Questionnaire (Horne, 
Weinman, & Hankins, 1999), was administered to describe the sample according to these 
beliefs and to conduct preliminary testing of the reliability of this instrument in this 
patient population for use in future studies. 
Design Rationale 
A qualitative descriptive method is desirable for this study because the subjective 
experience of managing RRMS among users and nonusers of injectable DMDs has not 
been fully explored. A qualitative descriptive approach uses naturalistic inquiry in order 
to “explicate the ways people in particular settings come to understand, account for, take 
action, and otherwise manage their day-to-day situations” (Miles & Huberman, 1994, p. 
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7). Naturalistic inquiry does not operate from pre-chosen study variables or a conceptual 
framework (Lincoln & Guba, 1985). Instead, it allows the phenomenon to emerge 
holistically, in context, through the perspective of the participant. The qualitative 
descriptive method organizes and analyzes the data, develops and consolidates themes, 
and summarizes and describes patterns related to the phenomenon. With minimal 
interpretation of the data, the subjective experience of managing RRMS is depicted 
exactly as it exists in patients’ lifeworlds. 
Setting 
Recruitment of participants took place at two local health care practices.  
Prospective participants were identified by health care providers at an MS clinic in the 
UMASS Memorial Health Center/University Campus, and a neurology practice at the 
UMASS Memorial Health Center/Memorial Campus. The researcher brought flyers (IRB 
approved) to the MS clinic and neurology practice on a regular basis to recruit 
participants and answer questions. Patients were given a flyer containing a brief 
description of the study and the investigator’s name and contact number. More than 720 
patients with RRMS are treated at either the MS clinic or the neurology practice. Of that 
number, approximately 60-80% are women. The preponderance of women patients is 
congruent with statistics regarding gender distribution in the literature (Anderson et al, 
1992). 
Sample  
Purposive, snowball, and theoretical sampling was used to achieve a sufficient 
sample for this study. Snowball sampling is a recruitment method whereby potential 
participants are referred by subjects already enrolled in a study (Faugier & Sargeant, 
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1997). Thirty-two (32) participants who met the inclusion criteria were enrolled. 
Maximum variation sampling was used to ensure a broad range of experiences from 
within the sample for comparison (Sandelowski, 1995). For example, participants ages 
ranged from 32 to 66; years with RRMS ranged from 8 months to 384 months (32 years); 
time on injectable DMD treatment ranged from 4 months to 132 months (11 years). 
Ongoing analysis of emerging codes and themes helped with theoretical sampling, and 
provided direction for further data collection (Coyne, 1997).  
The sample size was determined by the number of subjects and interviews needed 
to achieve theoretical saturation (Morse, Barrett, Mayan, Olsen, & Spears, 2002). 
Theoretical saturation occurs when themes are well established and described, and 
nothing new is learned from participants (Lincoln & Guba, 1985). Morse (1994) suggests 
that 30 to 50 interviews or observations represent an adequate size for qualitative studies. 
Of the 32 women recruited, 25 were on treatment, 6 ended treatment prematurely, and 
one woman had never initiated treatment. A second interview was conducted with 3 
subjects to verify data, explore new themes, and conduct member checks. Member 
checking involves going back to participants to clarify, correct, or validate assumptions 
made as the investigator analyzes the data (Lincoln & Guba, 1985). 
The investigator attempted to recruit a sample that was representative of the larger 
population. The majority of patients with RRMS are white women (approximately 60 %) 
(Anderson et al.,1992). Furthermore, attempts were made to recruit patients from 
different races and ethnicities. The study sites had little formal statistical information 
regarding the racial or ethnic makeup of the population. However, anecdotal information 
from the health care providers indicated that a very small number of African American 
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and Hispanic patients were treated at the MS clinic (larger site). Researchers suggested 
that the predisposition to RRMS is more likely among individuals with northern 
European ancestry (Compston, 1997). Immigrants who are more at risk for RRMS are 
African Americans and Asian Americans (Joy & Johnston, 2001). 
One patient who had never initiated DMD treatment and six patients who had 
discontinued treatment early were interviewed to gain an understanding of their 
perspective. An estimated 30% - 62% of patients are currently not using injectable DMD 
medications (Avasarala et al, 2007; Lo et al, 2005; Taylor & Leitman, 2001). The 
experience and perspectives of those patients may be different from those currently on 
the medication. Therefore, they are important individuals to interview. The health care 
providers at both sites had suggested that very few of their patients with RRMS who were 
eligible for the study were not on injectable DMD treatment. 
Inclusion Criteria 
Patients were eligible for this study if they met the following inclusion criteria: 
1. Women age 18 and ove 
2. Documented diagnosis of RRMS  
3.  Able to understand English 
4. Currently using or eligible to use DMD medications. 
5. Willingness to sign an informed consent 
6. Able to respond meaningfully in a 60 - minute interview 
7. MMSE > 24 
MS is a disease of young adults, affecting most patients between the ages of 20 
and 50 (Jacobson et al., 1997). RRMS is rare in children; less than 5% of children 
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younger than 18 are diagnosed with MS (Kalb et al, 1999).  Given these statistics, it was  
anticipated that there would be difficulty accessing an adequate sample of children. 
Moreover, the illness course and treatment regimens may be different for this population. 
Therefore, only women over 18 were included in the study. The MS clinic and neurology 
practice have few non-English speaking patients with RRMS; in fact, less than five non-
English speaking patients are treated at the MS clinic. Given the paucity of potential 
subjects, it was believed that it would be difficult to accurately describe this population. 
Therefore, only patients who could sufficiently communicate in English were included. 
Up to 60% of patients with RRMS may experience cognitive impairment, 
affecting attention, working memory, or information processing speed (Deloire et al., 
2005). Although considered to be mild in patients with RRMS, cognitive impairment may 
affect some patients’ ability to respond meaningfully to the interview questions. 
Therefore, prior to the interview, the investigator conducted a screening Folstein Mini 
Mental Status Exam (MMSE) (Folstein, Folstein, & McHugh, 1975). The MMSE 
evaluates cognitive intactness including memory, attention, recall, orientation, 
calculation, and language alterations. The instrument contains 11 items, is easy to 
implement, and takes 10 minutes to complete. 
Original implementation of the MMSE with a group of patients with various 
psychiatric and personality disorders, including dementia and pseudodementia (N = 206), 
and a group of non-cognitively impaired subjects (N = 63) yielded a test-retest reliability 
(Pearson coefficient) of r = .89 and an interrater reliability of r = .82 (Folstein et al., 
1975). Some have questioned the use of the MMSE due to its lack of sensitivity in 
detecting severe cognitive deficits in MS. However, Beatty and Goodkin (1990) found 
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that the MMSE is an effective screen for mild focal cognitive impairment in patients with 
RRMS. A score of 24 (of a maximum of 30) is considered to be an appropriate cutoff for 
inclusion in the study (Beatty & Goodkin, 1990). 
Procedures 
Recruitment of Study Participants  
The investigator was present at the MS clinic and neurology practice on a regular 
basis to recruit patients or answer questions. At other times, the health care providers 
(physicians, nurse practitioner) handed eligible and interested patients a flyer with the 
name and purpose of the study, and the investigator’ name and contact information. 
Interested patients signed a consent form that allowed the investigator to call them. The 
investigator called interested patients, explained the study, and answered questions. The 
investigator also recruited by snowball sampling. Flyers were given or sent to eligible 
women, and interested women were contacted for further discussion or consent. 
The investigator met with the potential participant to discuss the study, obtain 
consent, and conduct the screening Folstein MMSE. Interviews were conducted in an 
office in the UMASS Graduate School of Nursing or in a private office at the 
participant’s work or home. 
Data Collection and Management 
Pilot Procedure 
The entire research interview, including the qualitative interview, demographic 
survey, and Beliefs About Medicines Questionnaire, was piloted prior to the initiation of 
the study.  The aims of the pilot study included: (a) to identify problems in the research 
design, (b) to refine the data collection process, and (c) to become familiar with the 
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instruments, participants, and procedures (Burns & Grove, 2004). Two individuals with 
RRMS known to the investigator signed a consent form to participate in the pilot. Both 
participants’ interview forms and audiotapes were be labeled with a code and locked in 
the investigator’s office. The participants provided feedback that helped to improve the 
study procedures. The pilot interviews were included in the study. 
Qualitative Interview 
A face-to-face, semi-structured qualitative interview was conducted, using an 
interview guide (See Appendix A) to elicit: (a) the subjective experience of RRMS, 
including the day-to-day management of injectable DMD treatment; (b) important 
pre-determined factors (perceived barriers, side effects, adherence); (c) treatment 
beliefs (treatment necessity, specific concerns); and (d) ways in which health care 
providers influence patients’ treatment beliefs and management of the DMDs. 
Specifically, the interview questions helped to address the following specific 
aims: 
1) Describe the subjective experience of patients with RRMS as they manage 
injectable DMDs. Questions in the interview addressed daily life with the illness, 
including managing the injectable DMDs, experience of side effects, the effect of the 
medication on the patient’s life, and adherence issues. 
2) Examine the treatment beliefs of patients with RRMS related to injectable DMDs. 
Questions elicited the patient’s views regarding the necessity (benefits) of the 
medication as well as their specific concerns (e.g., side effects, financial burden, etc.), 
and how these beliefs influenced their management of the DMDs.  
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3) Examine the influence of health care providers on treatment beliefs and treatment  
management related to injectable DMD among patients with RRMS. Questions 
addressed the patient’s views on how health care providers influence their 
management of their injectable DMDs. 
 When interviewing the participants who did not initiate (n =1) or had stopped 
injectable DMDs (n = 6), a modified version of the interview was used (see Appendix 
B). 
The interview guide was revised during the study in order to fully explore new or 
emerging themes. Prior to the start of the interview, the investigator answered any 
remaining questions, reviewed the consent form, and obtained a signed informed consent. 
A copy of the signed informed consent was given to the patient, and the original was kept 
in a locked file in the investigator’s office. To maintain consistency and avoid 
misperceptions, the investigator asked the questions from the qualitative interview first, 
and then conducted the demographic survey and the Beliefs About Medicines 
Questionnaire with the participant. The entire session lasted approximately 60 minutes. 
Following the interview, the participant was asked if he/she was willing to be contacted a 
second time to participate in one additional interview (if necessary) to clarify, explore, or 
verify some of the data that is being collected for the study. A list of patients agreeing to 
be contacted was kept in a locked file by the investigator (subjects also indicated their 
willingness to be re-contacted by signing a separate line on the consent form). Each 
participant received a $20.00 stipend upon completion of the interview (and again if re-
interviewed). 
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Each qualitative interview was audiotaped by the investigator. Each audiotape 
was identified with a research number to maintain participant confidentiality. The 
subject’s name was not used during the taping of the interview. The audiotapes were kept 
in a locked file cabinet in the investigator’s office to be destroyed after publication of 
results. The audiotapes were transcribed verbatim. Simultaneous interviewing and 
analysis of the transcribed tapes allowed the investigator to uncover new themes and 
refine the qualitative interview. 
The original data forms were kept in a locked file in the investigator’s office. 
Each form was labeled with a research number that corresponded with the number on the 
participant’s audiotape, informed consent, and other research documents. A list of 
research numbers and identifiers were kept in a locked file in the investigator’s locked 
office. The quantitative data were entered into an SPSS 12.0 file created for the study. 
Entered data was checked against the original data documents. Frequencies were run to 
examine the data for missing or erroneous entries. In addition, backup files of all entered 
data were created on a regular basis. Only the investigator had access to the computer 
containing the research files.  
Quantitative instruments 
The following demographic data were collected from each participant: age, 
gender, race, education, employment status, marital/partner status, insurance status, years 
since diagnosis of RRMS, type of injectable DMD treatment, length of time on treatment, 
and self-reported adherence (see Appendix C). The 10-item specific subscale of the 
Beliefs About Medicines Questionnaire (Horne et al., 1999) (See Appendix D) was also 
administered. 
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The Beliefs About Medicines Questionnaire (BMQ) (Horne et al., 1999) is a 2-
section instrument, consisting of the Beliefs About Medicines Questionnaire-General 
(BMQ-General) (8 items) and the Beliefs About Medicines-Specific (BMQ-Specific) (10 
items). The BMQ-General discerns individuals’ attitudes toward medicines in general, 
while the BMQ-Specific assesses individuals’ beliefs about medicines prescribed for 
specific personal use. Only the BMQ-Specific was used for the purposes of this study in 
order to isolate participants’ views toward the injectable DMDs. 
The BMQ-Specific is composed of two 5-item scales: the Specific-Necessity scale 
assesses the belief about the necessity of the prescribed medication, and the Specific-
Concerns scale evaluates concerns about the disruptive, toxic, and dependent nature of 
the prescribed medication. Items are scored on a 5-point Likert scale, ranging from 1= 
strongly disagree to 5= strongly agree. The scores are summed to give a possible range 
of 5 to 25. Scores can be analyzed either on a continuous scale or dichotomous scale (at 
the midpoint), although the authors suggest that the continuous scale provides more 
information regarding the extent of the beliefs (Horne & Weinman, 1999). The necessity-
concerns differential can be calculated by subtracting concern scores from the necessity 
scores, with a possible range of -20 to 20. The result will depict the cost-benefit 
evaluation made by the patient; a negative score indicates more perceived concern than 
necessity, and a positive score indicates a higher perceived necessity than concern. An 
adherence study among patients with various chronic diseases (N = 324) found that 
positive necessity-concern differential scores were associated with higher adherence rates 
(r = 0.21, N = 324, p = <.001) while negative necessity-concern differential scores were 
related to lower adherence rates (r = 0.33, N = 324, p <.001) (Horne & Weinman, 1999). 
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The BMQ-Specific was constructed using a sample (N = 524) of patients with 
chronic illness. A preliminary Principal Components Analysis (PCA), and Exploratory 
and Confirmatory Factor Analyses were employed to develop and test the stability of the 
two factors. A replication PCA yielded identical items in the two factors. 
The internal consistency (Cronbach’s alpha) of the Specific-Necessity factor 
among chronic illness groups ranged from 0.55 (renal group, n = 47) to 0.86 (general 
medical in-patient group, n = 90). Regarding the Specific-Concerns factor, the internal 
consistency ranged from 0.63 (psychiatric group, n = 89) to 0.80 (diabetic group, n = 99). 
Test-retest reliabilities (Spearman correlations) among asthmatic patients (n = 31) were 
0.77 (p = < 0.001) (Specific-Necessity) and 0.76 (p = < 0.001) (Specific-Concern). 
Subsequent utilization of the BMQ-Specific reported an internal consistency (Cronbach’s 
alpha) of 0.82 (Specific-Necessity) and 0.71 (Specific-Concerns) (Horne & Weinman, 
2002). This scale has not been used in patients with RRMS. Therefore, the internal 
consistency reliability of the scale was evaluated in the proposed sample (taking into 
account the small sample size). 
Field Notes 
At each interview session, the investigator used field notes to record observations, 
notes, and reflections (Creswell, 2003). The observations included participant behavior, 
time and setting of the interview, and other pertinent information. Reflections were 
related to the observations, the interview responses, or other personal insights. The field 
notes were organized in a notebook, labeled with an identifying number and locked with 
the other study documents.  They were used during analysis to provide context for the 
data analysis (Creswell, 2003). 
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Data Analysis 
Data analysis 
The investigator used qualitative content analysis to examine the data. Qualitative 
content analysis uses a systematic format to develop codes, or labels, to describe data 
from careful reading of the interview transcripts (Morgan, 1993). A codebook was 
created that listed, organized, and arranged codes and data according to predetermined 
criteria. The purpose of coding was to cluster large pieces of data into a smaller number 
of focused, descriptive themes (Miles & Huberman, 1994). Codes were consolidated 
where possible, and ongoing attempts were made to compare and contrast patterns within 
and across data (Creswell, 2003). Some of the codes referred back to the organizing 
framework; others emerged during analysis (Sandelowski, 2000). 
The codes were examined for threads of larger themes. The sampling strategy and 
interview guide was revised in order to explore emerging themes. A summary of the data 
included specific quotations or narratives that substantiated the themes. Minimal 
interpretation by this investigator allowed the experience to be portrayed as it was 
described by participants. 
Quantitative data from the demographic instrument and the Beliefs about 
Medicines Questionnaire (BMQ) was analyzed using SPSS 12.0. The data were used to 
describe the sample. An attempt was made to link the quantitative data from the BMQ 
with the qualitative data in order to examine potential themes (Miles & Huberman, 1994). 
Trustworthiness 
 According to Lincoln and Guba (1985), trustworthiness in qualitative inquiry 
relies on four components: credibility, transferability, dependability, and neutrality. The 
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investigator attempted to ensure credibility by spending sufficient time in the field, 
identifying and documenting personal a priori biases, correcting misconstrued 
perceptions through member checks, and developing a relationship of trust and 
confidentiality with the participants. Transferability was addressed by purposeful 
sampling and constructing thick, rich descriptions of the phenomenon. Dependability and 
confirmability involved an auditing of the research process. The investigator regularly 
consulted with her dissertation advisor to ensure appropriate oversight of the process; 
moreover, field notes and a reflexive journal were used to record reflections, decisions, 
and methodological issues that were encountered during the study.  
Limitations  
 It was anticipated that there would be several limitations related to the design of 
this study. First, the cross-section design and small sample size prevented generalizability 
of the findings beyond the study sample. Furthermore, individuals who volunteered to 
participate in the study may not have had the same experience as those who did not 
participate. Finally, the limited sample size prohibited a complete psychometric analysis 
of the BMQ.  
Protection of Human Subjects 
Approval was obtained from the UMASS Committee for the Protection of Human 
Subjects in Research. Participants were informed about the purpose and procedures of the 
study. They were also told about their rights, including the assurance that: (a) they may 
withdraw from the study at any time without jeopardizing care (b) they may ask questions 
at any time during the study, and obtain a copy of the results; (c) their responses would be 
kept confidential and private as mandated by HIPAA, and (d) all documents pertaining to 
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them would be destroyed after completion of the study. Each participant was asked to 
sign a consent form that met IRB and HIPAA guidelines. Although unnecessary in this 
study, any early withdrawal from the study would have been documented and reported. 
Risks 
 The risks involved in the interviews were minimal. The purpose, benefits, and 
procedures of the study were discussed with the patient. Reassurances were given 
regarding the confidentiality of audiotaped and written references to the participant. The 
interview was conducted in an unhurried, calm manner, and participants were given 
sufficient time to answer. Participants were reminded that they could turn off the tape 
recorder at any time during the interview, and the interview could be terminated at the 
participant’s discretion. This, however, did not occur. 
It is possible that a positive emotional response could occur with the opportunity 
to share personal perspectives with this investigator. However, particular interview 
questions may be distressing to the participant. Patients were told that if they become 
distressed during the interview, they would be asked if they wish to stop. Referral to 
mental health agencies or other resources for evaluation were available. However, none 
of the participants required referral for mental distress.  
Data Management 
 Confidentiality with participant data was accomplished by assigning identifying 
number codes to each set of audiotapes, qualitative and quantitative documents, and tape 
transcripts. A list of codes and corresponding identifiers were kept locked in the 
investigator’s office. Interview documents were collected, checked for completion, and 
stored in a locked file accessible only by the investigator. The quantitative data were 
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entered into an SPSS 12.0 database on a laptop computer with an access password known 
only to this investigator. 
Conclusion 
 The purpose of this qualitative descriptive study was to examine the subjective 
experience of women as they managed RRMS and DMD treatment. In addition, beliefs 
about the DMDs and the influence of health care providers in patients’ treatment beliefs 
and management of injectable DMDs were explained. Patients with RRMS who were 
currently undergoing injectable DMD treatment, as well as those who never initiated or 
who had stopped treatment, participated in the study. The organizing framework, Beliefs 
About Medicines, guided the study. Common themes related to the phenomena emerged.   
Qualitative content analysis was used to analyze the interview data, and descriptive 
statistics were used to analyze the demographic and BMQ-specific results. 
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Chapter IV 
Results 
 Qualitative descriptive methodology was used to study the subjective experience 
of the day-to-day management of RRMS among adult women who were currently using 
injectable DMDs, had stopped using injectable DMDs, or had never used injectable 
DMDs. The results revealed two overarching themes, Uncertainty and Control, and three 
subthemes, Adjusting (limitations, changes , strategies, and attitude), Bothersome 
Symptoms/Side Effects and Motivation (fear and hope). Sample characteristics and a 
description of the overarching themes and subthemes, with illustrative participant quotes, 
follow. The results are organized by each study aim. The themes and subthemes are 
depicted in a schematic as a parallel process. (Figure 2) Results for the first two aims will 
be presented in an integrated manner. 
Participants 
 A total of 32 women were recruited for a one-time, face-to-face interview which 
lasted approximately 60 minutes. Interviews took place in a private room at UMASS 
Memorial Health Care Center (n = 19), at participants’ work (n = 4), or in their home (n = 
9). Prior to the interview, each participant completed the Folstein Mini Mental Status 
Exam (MMSE). All of the women scored greater than 24 on the MMSE. Each qualitative 
interview was followed by a demographic survey and the Beliefs About Medicines 
Questionnaire (BMQ). Recruitment was ongoing until the researcher determined that 
information redundancy was reached and no new information was revealed. The data 
collection occurred from February, 2006, to June, 2006. Frequencies were run and 
revealed no missing data from either the demographic surveys or BMQ instrument. 
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 Figure 2. A Parallel Experience of Managing RRMS and Injectable DMDs 
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Key: 
RRMS: Relapsing-remitting multiple sclerosis 
DMD: Disease Modifying Drug 
SX: Symptoms  
SE: Side effects 
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Ninety-four per cent of the women were white, which is consistent with the overall 
prevalence of individuals with RRMS by race (Anderson et al., 1992). The mean  
age was 47. Most of the women were married or living with a partner (91%), reported 
having a post-secondary education (75%), and were working at least part time (72%).  
Four of the women (12.5%) were nurses. The average length of time with RRMS was 99 
months (8.2 years). The average length of time using injectable DMDs was 37 months 
(3.1 years). Demographic characteristics of the sample are contained in Table 8. 
Use of Injectable DMDs 
Of the total number of participants, 25 women were using injectable DMDs, 6 
discontinued injectable DMDs, and 1 never started injectable DMDs. The most 
commonly used injectable DMD was IFNB-1a IM (Avonex) followed by glatiramer 
acetate (Copaxone),  IFNB-1b (Betaseron), and IFNB-1a SC (Rebif). Six women (19%) 
switched to their present therapy from a prior DMD; three of those women switched more 
than once. The most common change was from glatiramer acetate (Copaxone), a non- 
interferon DMD, to IFNB-1A IM (Avonex), an interferon DMD. The most common 
reason for switching was worsening disease (n = 5). Two women who discontinued 
treatment reported switching DMDs (once). A record of DMD usage is located in Table 
9. 
Overarching Theme and Subthemes 
Two overarching themes and three subthemes emerged from women’s responses 
regarding their experiences. The overarching themes, uncertainty and control, were 
present in all interviews. Issues of control were integrated throughout the data. Women 
described adjusting to RRMS, including limitations and changes. They also described a 
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‘parallel experience’ in managing their RRMS and their injectable DMDs, which 
encompassed bothersome symptoms/side effects, and strategies. Women discussed 
developing a positive attitude to adjust to the bothersome symptoms and uncertainty. 
Fear and hope were described as motivators for continuing treatment; they intersect with 
women’s parallel management of their RRMS and injectable DMDs. 
Aim 1: Describe the subjective experience of women’s day-to-day management of 
RRMS among those who are currently using injectable DMD therapy, have never used 
DMD therapy, or have stopped using injectable DMD therapy. 
RRMS: Bothersome Symptoms 
Bothersome is defined as “causing annoyance and inconvenience” 
(www.encarta.msn.com/dictionary). 
Most of the participants (n = 28) reported having bothersome symptoms or functional 
impairments. The most common symptoms or impairments included fatigue, difficulty 
walking, cognitive issues (memory, thought processes, word recall), and numbness. 
Commonly reported symptoms are listed in Table 10. 
Fatigue was reported as the predominant and most distressing symptom. Two 
women termed their fatigue ‘depressing.’ One woman claimed that MS was called the 
‘tired disease.’ Common characteristics of fatigue included: occurring later in the day; 
exacerbated by the lack of sleep, heat and excessive activity; and requiring naps or rest 
periods. One woman’s fatigue was increased before her menses. One woman described 
the intensity and unpredictability of her fatigue: “I get half way through the market and 
feel like I couldn’t take another step. An’ I have left my stuff and gone home. Or not 
gone to do the next errand. I just — it can be so sudden.” 
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The women described their walking problems in terms of balance issues, leg pain, 
weakness, and limping. One woman described her leg pain, “I will get leg spasms 
occasionally but they don’t last . . . for 12 hours or less, and they really don’t affect my 
walking ability . . . . and they seem to come when I am very tired.” Other women stated 
that their foot dragged, causing them to limp, especially when they were tired or walked 
long distances. Four women discussed monitoring their legs, when walking, to avoid 
tripping or falling. “If I spend a lot of time walking and stuff. . . . I have to really pay 
attention to where my leg is, so I make sure it doesn’t, like, give out on me or. . . . that I 
don’t trip or fall.” One woman described having to ‘mentally tell her legs to move.’ 
Another woman needed to arrange her living space to avoid injury from falls. “. . . . even 
just getting out of bed, I don’t know if my legs are going to hold me up. . . . if the kids 
leave a toy there or my husband, the socks on the floor, I still have to make adjustments.” 
Cognitive issues included problems with memory, word recall, and thought 
processing. The most common complaint was memory loss. Women also reported 
forgetting words or misplacing items.  Two women mentioned a more severe memory 
problem. 
Um, the only piece that never changed in that way is I can read a book and I 
cannot tell you what the book is about when I get to the end. I can go to the 
movies and watch a movie and I cannot tell you what the movie is about when I 
get out. I don’t remember it.  
Others suffer from word recall. One woman stated, “It’s just — I can start a sentence and 
I can’t find a word that I’m looking for. And it just makes me shy away from talking to 
people at times.”  
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Women reported facial, limb, and genital numbness. The most common numbness 
occurred in the hands. One woman described the sensation: 
It’s almost like, how I explain to my children, I said, put a glove on your hand. 
That is what my hand is like every day. Pretend you have to try and wash dishes 
with that glove on. You have to zipper your coat or button your jacket or make 
dinner with that glove on. That is what it feels like for me. . . . on a bad day I said 
now put a mitten on you and try zippering your jacket. That is the best way that I 
can explain the numbness there. 
The numbness was transient for some but constant for others. Women reported stress (n = 
2) and warm water (n = 2) as precipitators of the numbness. One woman described the 
effect of numbness in her hands on her fine motor skills. “Sometimes I can’t put my 
earrings in or the clasp of my chain. . . . then I just get mad, and yell, ‘I can’t do this.’” A 
woman reported that genital numbness negatively affected her sexual relationship and 
ended her marriage with her husband. 
Uncertainty 
All of the women described a sense of uncertainty related to RRMS. Women 
discussed uncertainty about the future (n = 11), including becoming a burden, having to 
be in a wheelchair, having to stop working, or what would happen to their children. Other 
areas of uncertainty included relapses (n = 6), functional status (n = 5), MS-related 
symptoms (n = 3), course of illness (n = 3) and worsening disease (n = 3). One woman 
described each uncertain day as a “grab bag.” “My family knows, I say to them, it’s like a 
‘grab bag’ every morning. I wake up and think, okay, what’s it going to be like today? 
Will I be able to walk? Will my vision be bad?” A woman with few symptoms described 
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the effect of constant uncertainty: “It’s like always in the back of my mind. Um, the 
wondering, like, what’s going to happen to me…am I going to continue feeling the way I 
do. . . . or is the bottom going to fall out. . . . and when?” Another woman referred to the 
unpredictability of relapses, “It sucks, in plain English. . . . you don’t know when it’s 
going to hit you again. . . . you have to live day to day.” 
One woman described how she hid her feelings of uncertainty: “Outwardly, I 
pretend nothing is wrong with me and I’m just fine. . . . inwardly, it’s so uncertain that I 
don’t know what tomorrow is going to bring.” Another woman described how 
uncertainty prevented her from making future plans. “. . . . You want to make plans for 
retirement and we want to do this and go here. . . . I would like to be excited about these 
things. . . . but are we ever going to be able to do those things?” 
Adjusting: Limitations, Changes, Strategies, and Attitude 
Adjusting (adjust) is defined as “to adapt to a new environment or condition” 
(http://encarta.msn.com/dictionary). Women described ways that they had adjusted to 
their RRMS through terms like “compensating,” “modifications,” “accommodating,” and 
“making changes.” “But really, my life, the whole picture has been like one big 
compensation. I just fit my life into the MS.” Some women (n = 10) described their 
RRMS positively, using terms such as “normal,” “stable,” “mild,” “healthy,” and “not 
very difficult.” “I work the same. I am still taking care of my kids and going to their 
functions. I do everything that I normally do. I just get a little more tired at night.” One 
woman said, “It’s normal living. . . . only every day when you get your butt out of bed. . . 
. you say ‘Thank you, God’ and you just go on and do your day.” Other women (n = 15) 
used more negative terms, such as “discouraging,” “frustrating,” “difficult,” “a 
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challenge,” and “depressing.” Two women described their bodies as being “out of 
control.” Yet, even with negative terms, some women described how they adjusted. “It’s 
discouraging sometimes. . . . I live with it. . . . I try to make people laugh. . . . if I’m 
making somebody else laugh, then I feel like I’m laughing, too.” A woman stated, “It’s a 
little depressing. . . . you can deal with it, you know?” Another woman said, “You learn 
to live with it. . . . it’s what life dealt you.” 
Women’s adjustment to their RRMS did not seem to be influenced by the number 
of years with RRMS or current treatment status (on treatment, off treatment, never started 
treatment). For example, one woman with RRMS for 4 years (and not using DMDs), 
stated, “I do everything everybody else does but. . . . I get really tired. . . . I just don’t 
have the energy to do the things I want to do. . . . I keep going.” Another woman with 
RRMS for 10 years (and using DMDs) said, “It’s discouraging sometimes. I try to cover 
it up as best as I can. It’s just — it’s not what I had expected at this point in my life . . . . 
the loss of physical use on my right side.” A third woman, who has lived with RRMS for 
22 years and never started DMDs, reported issues with balance, memory, numbness, and 
bladder control. Yet she stated, “I would have to say, to me, it’s a perfectly normal 
lifestyle, like everyone else’s lifestyle.” Women described limitations and changes in 
their lives due to bothersome symptoms and uncertainty. 
Limitations  
Women described limitations on their life due to their RRMS. Persistent or 
bothersome symptoms, including fatigue or impaired walking, limited activities such as 
extensive walking (n = 11), participating in social events (n = 8), and housework (n = 4). 
One woman described having to limit her walking distance and speed. “You’re limited as 
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to how much you walk because you get too tired.” Some women reported that 
bothersome symptoms forced them to limit their housework. One woman described how 
she had to do her housework in segments: “I get up and I start my breakfast and take it 
easy. . . . I do something an’ I’ll sit down and relax a little while. . . . laundry. . . . that’s 
about it.”  Another woman described how fatigue caused her to limit her errands. “It’s 
like, I can’t go to Walmart and the grocery store on the same day. . . . ’cause if I do, I’m 
exhausted.” 
Some women described how they had to acknowledge that certain activities were 
no longer possible. “I used to take my dog for walks. . . . I can’t now because my foot 
drags.” Yet, other women purposely continued with their routine. “I deliberately walk my 
dog every day and I deliberately go up and down stairs. . . . and go to the market. . . . but 
often, by the end of the day, I’m tired and my left leg will drag a little.” 
Three women described how their RRMS affected their social life.  One woman 
stated, “Well, the social life — you go out. . . . you cannot really do nothing but sit there 
and look at people.” Another woman said, “. . . . your friends will spend the day doing 
something and then go for dinner. . . . then go dancing. . . . I have to go home. . . . I feel 
like I’m holding my husband back. . . . he’s saddled with me.” Some women also 
discussed the limiting impact of RRMS on their family activities. Women described 
difficulty in attempting to play with their children or grandchildren, attend their 
children’s activities, or enjoy summer vacations or outdoor activities in the sun. 
Despite limitations, some women described important functions they were able to 
manage. One woman stated, “I had to sell my business. . . . it was very hard to work the 
way I was and have MS. . . . I’ve still been able to maintain a house, a home, raise a 
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family and enjoy everything I’ve ever enjoyed.” Another woman described how she 
overcame her limitations. “It (RRMS) doesn’t limit me. . . . either I’ve gotten used to 
things like my slight residual numbness in my feet or learned to work around it.” 
Changes 
Women discussed the changes that occurred in their lives with RRMS, including 
changed self-identity, relationships, priorities, and plans. Women described how their 
RRMS caused changes in their self-concept. One woman talked extensively about the 
significant impact her RRMS had on her self-identity. “I went through a year and a half 
to two years of hell just in — in getting a grip on. . . . who and what I was going to be as 
a person with MS — because my identity changed.” Another woman stated, “. . . . I’m 
not perfect. . . . there’s something wrong with me.” Two women with fatigue and walking 
impairments jokingly referred to themselves as ‘old lady.’ Many women (n = 8) 
compared their condition to others with MS; some felt grateful that their illness was not 
as extensive, while others worried that they might someday experience similar disease 
progression. “But I see people at church that have it…and I see what they’re going 
through. . . . on disability, not working. . . . is that going to happen to me?” 
Women discussed the change in relationships with family and friends due to the 
RRMS. One woman who had difficulty initially accepting her diagnosis spoke of her 
need to leave friendships during her transition. “I’ve come to a place in my life where 
I’ve accepted what’s going on with me. . . . this is my reality, and I have got to get my 
life around it, and if you can’t, I have to leave you behind.” She described discovering 
new friends who were willing to listen and help her to redefine herself with her illness. 
Another woman described the variability of responses by others to her RRMS: “There are 
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times when. . . . my close friends or family. . . . they’re either over-solicitous, ‘Oh are you 
sure you can do this? Are you tired? ’ or they just think I can do the same things. . . . I 
always did.” 
A woman described her family’s transition as she adjusted to her RRMS: “. . . . 
they were treating me with kid gloves and, um, I don’t have that personality. . . . it was 
hard for them to know how to deal with me. . . . they are much more accepting and ready 
to talk about things and deal with things.” One woman worried about the added 
responsibility her RRMS put on her husband. “You know, my husband is — he’s also 
retired. It’s put more responsibility on him. Physically and mentally. He hates when I 
don’t feel well. You know, and he worries about me, which I feel real bad about.” 
The diagnosis of RRMS caused many women to evaluate their current situation 
and future plans. Women discussed changing priorities to minimize the effects of RRMS 
and maintain their quality of life. Women modified educational goals, vacations, and 
retirement plans.  One woman described how she scaled back her goals to accommodate 
her RRMS. “I used to be a very high goal setter. . . . because I got sick, I wasn’t able to 
do as well as I anticipated. So I kind of minimize what I think my maximal potential 
could be.” Another woman discussed her decision to actively pursue her goals after her 
diagnosis. “So what can I do today because it’s something I should do or always wanted 
to do, and ten years from now I may not be able to?” She described her plans to further 
her education. 
Two women spoke of changing vacation plans because of heat intolerance, while 
two other women described scheduling long-awaited vacations earlier while they were 
functional. “My husband and I will take more vacations than we did before, that type of 
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thing. Because there are things I want to see and I’m still able to do that.” Four women 
discussed engaging in healthier lifestyles, including exercise, diet, and smoking cessation. 
Four other women described plans to make permanent adjustments to their houses in 
anticipation of the future. 
Strategies 
Women described strategies to control the physical impact related to RRMS, 
including modifying their environment or lifestyle and managing symptoms. “I get things 
done in completely different ways.” A list of symptoms and strategies are in Table 11. 
Some women reported being sensitive to triggers of their RRMS symptoms, and 
adjusted their environment or lifestyle to avoid them. Four women identified stress as a 
trigger to the onset of symptoms, which include fatigue, limping, neuropathy, and vision 
changes. “Stress seems to be a trigger, at least for me. I have certain symptoms like that 
numbness. . . . It’s almost like an indicator. I have to calm down and relax whatever the 
stress or heat or severe cold sometimes.” 
Many women (n = 10) accommodated their fatigue by avoiding the heat, taking 
naps, adjusting work, asking for help with chores, and slowing down. One woman had air 
conditioning installed to minimize the effects of the heat. Some women (n = 4) verbalized 
frustration that they had to nap or rest during the day. “I take naps. . . . that’s something I 
didn’t used to do. . . . sometimes it bothers me that I just can’t get through my whole day 
without a nap. . . . that part is hard to adjust to.” Others (n = 4) spoke of ‘pushing 
through’ their fatigue as a way of maintaining a normal life. 
Six women reported that they had altered their work life due to the RRMS. Some 
women retired early (n = 2), while others stopped working (n = 2) or reduced their 
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schedule (n = 2). One woman perceived the decision to leave her stressful job as a 
positive change for herself and her family. “So we decided to see if we could try to make 
do without me working. . . . without the MS diagnosis, I don’t know if we would have 
made that decision. In one way, it has actually helped.” Another woman described how 
having to stop working negatively affected her social life: “I mean, I’m not saying work 
is great. . . . but it was just — it was a way out, you know, and then you can talk with 
other people. . . .” 
One woman laughingly described how she resolved her reluctance to let others 
help in the house. “. . . . it was hard for me to give up control over. . . . how the house is 
managed…I still try to do that by having the person who is ‘best suited’ for the things I 
need them to do.” Two women discussed how learning to slow down had a positive effect 
on their life. “I was always on the go. . . . but I never enjoyed what I was doing. . . . now I 
notice the flopping of the dog’s ears, or I notice my daughter is laughing a little bit deeper 
or longer. . . .” 
Some women described addressing their walking difficulties by monitoring their 
legs, walking with others, and utilizing supports. “Because I have weakness in my left 
leg, I always have to be paying attention to what that leg is doing so that I don’t trip.” 
One woman described how she no longer took walks alone: “I used to go out walking a 
lot, you know. . . . alone. . . . I’ve had a couple of falls, and I just — I prefer to have 
someone around me.” One woman described how pushing her grandchildren in their 
stroller allowed her enough balance to continue taking walks. 
Two women reported using handicapped license plates to conserve energy and 
accommodate walking abilities. Three women with cognitive difficulties spoke of writing 
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things down to remind themselves of important tasks or appointments. Two women 
described having to read and reread material to refresh their memory.  
Positive attitude 
Women’s attitudes toward their RRMS were important components of adjustment 
to the RRMS. One woman reported that taking a proactive approach in managing her 
illness helped her to have a positive attitude. “Kind of altering your lifestyle and making 
things a little bit easier for you. Understand your limits, I think, has a lot to do with how 
well you do.” Another woman stated, “I guess you make changes. You do modifications. 
Other than that, I just live life like I don’t have MS. You know, I look on the bright side 
of things. I keep positive in my attitude.” Another woman stated, “I don’t let MS rule my 
life. . . . I refuse to as long as I can.” One woman asserted that she maintained control of 
the RRMS, “You have to be the boss of your body. . . . I have MS but MS isn’t going to 
control me. . . . I’m the boss.” 
Attitudes were dependent on women’s illness status. One woman stated her lack 
of symptoms over the years made it easy for her to cope. “. . . . the fact that I haven’t had 
symptoms and it’s now been going on six years since my official diagnosis, you start 
feeling like, okay, I can live with this.” Three other women described their RRMS as a  
“mild case,” and asserted that their attitude might be different if their status changed. 
Two women focused on the things they could still do; for example, raise a family, 
work, or walk the dog. Some (n = 4) had the attitude there was nothing they couldn’t do, 
and were doing everything they wanted to at that time. “I’ve learned to live with what I 
have and again, I am just going to do as much as I can.” Three women discussed using 
humor to cope with their RRMS. One woman stated, “The day the doctor told me I had 
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MS, I said to him, ‘Good, now I can park in those places with the little round chairs.’” 
Other women (n = 4) reported that their faith helped them adjust to the diagnosis. “With 
my faith, I know that and I’ve accepted what — the disease I have and I know that 
through my faith, I have to continue this course. This is what’s been offered to me.” 
Injectable DMDs: Bothersome Side Effects 
As part of their management of their RRMS, most women (n = 25) were currently 
using DMDs. More than half of the women using injectable DMDs (56%, n = 14) 
reported experiencing flu-like symptoms as the most common systemic side effect. 
Women described a constellation of symptoms, including headache, fever, chills, chest 
discomfort, insomnia, and muscle pain. Flu-like side effects were most often reported by 
women using interferon-beta 1a IM (Avonex) (n = 11), interferon-beta 1b (Betaseron) (n 
= 2), and interferon-beta 1a SQ (Rebif) (n = 1). One woman described how she felt after 
the injection: “the next day. . . . I’ll say to my husband, I don’t even feel human today.” 
Two women stated their flu like symptoms were constant; one of the women expressed 
distress at causing her symptoms, “It’s painful. My chest gets really. . . . I curl up. . . . in a 
fetal position. Every muscle tightens. . . . and it’s hard, knowing that I’m doing that to 
myself.” She confessed that she would skip injections or squirt out medication to avoid 
the severe side effects. Other side effects included elevated liver function tests (n = 2), 
low back pain (n = 2), and production of antibodies (n = 1). 
Three women reported their side effects had diminished over time. However, nine 
women reported that the symptoms were variable and unpredictable. In fact, one woman 
questioned whether her occasional insomnia and ‘hot flash’ were due to the injectable 
DMD or menopausal symptoms. The side effects could appear several hours after the 
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injection and last up to 48 hours. One woman compared the unpredictability of the DMD 
treatment effects to the unpredictability of her RRMS: “I used to try Advil at night. . . . 
but it’s almost like MS itself. . . . sometimes, the medicine, you respond differently on 
days. . . .” The flu-like side effects seemed to be influenced by the injection location, time 
of day, adequate hydration, and premedication with analgesics. Injection into the arms 
seemed to intensify the side effects and injecting into the buttocks mitigated the side 
effects. Most of the women (88%, n = 22) reported injecting their DMD at nighttime to 
allow them to sleep through side effects. 
Women described missing work or social events due to the occurrence of severe 
side effects. Some women stated family and friends knew to refrain from calling or 
visiting after the injection. “People know not to call for a couple of days. When I make 
plans, it has to be towards the end of the week. So it’s changed the way I do things.” 
Adjusting: Attitudes and Strategies 
Adjusting to the injectable DMDs included the perception by women of their 
ability of women to control or cope with its impact on their lives. Eleven women used 
positive terms in describing their management of their DMD therapy, including “easy,” 
“a piece of cake,” “no big deal,” “just a routine,” “so automatic,” and “part of my life.” 
Three women stated how they “fit it into their life.” An equal number of women (n = 11) 
used negative terms to describe their experience: “I don’t love it,” “extreme 
inconvenience,” “horrible,” “gives you the heebee jeebees,” “I hate it,” and “worst part of 
the disease.” 
Women used terms or phrases that depicted how they perceived their DMD, 
including “insurance policy,” “empowering,” “part of the big plan,” and “something to 
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believe in.” Other participants described the injectable DMDs as “not so bad” and 
“bearable.” A woman felt that her attitude toward the DMD diminished its negative 
effect: “It’s not an inconvenience in my life. It’s my lifesaver. It’s a different mindset.” 
Some women described how the injectable DMDs had become a routine part of 
their life. “. . . . it’s so automatic. . . . now it’s just part of my life. . . . I’ll do this every 
other night and hopefully it will keep things at bay. . . . ” Another woman said, “It’s just 
like brushing my teeth. . . . it’s like what you do. . . . it’s part of my daily routine.” 
Three women described how their DMD increased their quality of life. “It’s made 
my quality of life better. . . . it has allowed me to do the things I’ve wanted to do.” 
Another woman claimed, “It’s going to give me a good life.” Women stated they used the 
injectable DMDs because they wanted to keep walking and did not want to “get worse” 
(n = 8), or “end up in a wheelchair” (n = 6). Three woman discussed feeling responsible 
to use the injectable DMDs; one, a nurse, stated, “I’d feel. . . . if something did happen 
and I got more lesions, I’d feel like. . . . I’m not trying to make myself better.” Another 
nurse expressed, “I’m in the health care profession. . . . I believe in. . . . trying to treat a 
problem. . . . can’t leave everything in God’s hands.” 
Women described the importance of control while using the injectable DMDs. 
Two women indicated that using the DMDs made them feel in control; one said, “. . . . 
the biggest thing I feel is in control. . . . when you can do something so small to give 
yourself a sense of being in control. . . . it is something you can do that’s positive.” 
Another asserted, “So if giving yourself a shot every day is going to help you control the 
MS, which you have absolutely no control over anyway, then you put up with a little 
grief.” In referring to the negative aspects of the DMDs, one woman stated, “So, again, 
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it’s an inconvenience, but you can control that.” Conversely, a woman who discontinued 
DMD therapy reported feelings of lack of control. “The medicine made me feel like. . . . I 
didn’t have control of me. . . . I just didn’t feel like myself.” Women described strategies 
that helped them to adjust to their DMDs. 
Strategies 
 Women described their strategies concerning management of their injectable 
DMDs in great detail. Women chose days of the week and times of the day that were 
convenient for them. Most of the women received their injection at night and at home. 
Almost half of the women (n = 12) premedicated with either acetaminophen or 
ibuprophen to mitigate side effects; other women stated they felt they no longer needed to 
premedicate due to reduced side effects. Nine women reported rotating sites arms, legs, 
buttocks and hips. One woman advised, “Find a healthcare professional that can really 
stab you in the butt. . . . it has eliminated pretty much all of the side effects and the ones 
that still linger are very manageable.” 
Other strategies included the use of ice, a calendar or schedule, an injection grid 
(to keep track of rotating sites), and a quiet place. One woman described how she 
‘personalized’ her regimen: “I had a cardboard box for the longest time. . . . I finally said 
this is for me. . . . I have to do something nice. . . . I bought myself a nice tray.” She 
reported that the special tray was a helpful reminder to take her shot. Common injection 
issues or side effects and useful strategies are located in Table 12. 
 Sixty-four percent of women (n = 16) reported never skipping their injectable 
DMDs, while 36% (n = 9) skipped one or more doses. Reasons given for skipping 
medication included vacations (n = 4), emotional distress (n = 3), and bothersome side 
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effects or injection issues (n = 3). One woman described feeling ‘in control’ when she 
decided to skip an injection: “. . . . it’s just sometimes you get fed up with everything and 
it’s one thing you have control over. . . .” Another woman described getting angry at her 
DMD, “I’ve looked at those injectables and I just picked it up. . . . I’m not taking you 
tonight. . . . I was angry at it. . . . I guess it was just my way of dealing with it that night.” 
One woman described skipping many daily injections due to painful skin reactions before 
finally switching to another injectable DMD. She professed to ‘feeling guilty’ and that 
she ‘was failing them’ (health care providers) by skipping her doses. 
Six women reported occasionally missing an injection due to forgetting, 
procrastination, or illness. One woman reported feeling guilty for missing a shot. “It’s 
like Monday night. . . . my husband’s already asleep, he can give it to me tomorrow 
night. . . . in the back of my mind, I need to take my medication. . . . if I tell my mother, 
she’s all down my throat. . . . I feel even more guilty!” One woman, who was a nurse, 
emphatically denied skipping injections. “Absolutely not. The nurse in me would never 
allow that to happen!” 
Aim 2: Examine treatment beliefs, including treatment necessity and perceived concerns, 
related to injectable immunomodulator therapy among women with RRMS who are using 
or not using injectable DMD therapy. 
Aim 2 is presented using both quantitative and qualitative data. The Belief About 
Medicines Questionnaire (BMQ) was utilized in this study to determine women’s beliefs 
about their injectable DMD. The BMQ consisted of 10 statements using a 5-point Likert 
scale that ranges from strongly disagree (1) to strongly agree (5). The necessity-concerns 
differential was calculated by subtracting concern scores from the necessity scores, with a 
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possible range of -20 to 20. The results reflected the cost-benefit evaluation made by the 
patient; a negative score indicates more perceived concern than necessity, and a positive 
score indicates a higher perceived necessity than concern. Despite the limited nature of 
our sample (N = 32), the internal consistency reliability (Cronbach’s alpha) was 0.89. 
Therefore, the BMQ has good reliability in this sample. The results from the BMQ can be 
found in Table 13, and will also be integrated with the qualitative findings. The necessity-
concern differential will be included in the discussion under Treatment Concerns. 
According to the Belief About Medicines framework (Horne and Weinman, 
2002), patients’ treatment beliefs are influenced by information or experiences related to 
the prescribed medicine, and perceptions of personal identity and control. Patients 
participate in a continual process of weighing perceived needs for the medication (e.g, to 
improve or maintain health) against concerns regarding the medication’s effect on day-
to-day living (Horne & Weinman, 2002). Feelings of uncertainty and control were 
threaded throughout women’s responses about their beliefs regarding the injectable 
DMDs. Several women described a process of ‘weighing the pros and cons’ in deciding 
to start or continue the injectable DMD treatment. Most women identified fear and hope 
as motivators for continuing treatment. 
Treatment Necessity 
Treatment necessity is the belief that a particular medication is essential for 
treatment. Perceived need is individual and may be influenced by several factors, 
including beliefs about medicines in general, prior experience with the medication, illness 
beliefs, filtered information, and social or cultural expectations. Five statements in the 
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BMQ addressing women’s beliefs about treatment necessity are integrated with the 
qualitative data. 
Three statements on the BMQ addressed women’s perceptions of treatment 
necessity related to maintaining their present and future health and preventing disease 
progression. Based on the responses, women believed that their present and future health 
depended on the injectable DMDs. In response to the statement, “My present health 
depends on the injectable DMDs,” 44% per cent (n = 14) agreed, 34% (n = 11) disagreed, 
and 22% (n = 7) were unsure. When addressing the statement, “My future health depends 
on the injectable DMDs,” 59% (n = 19) agreed, 22% (n = 7) disagreed, and 19% (n = 6) 
were uncertain. Moreover, women responded that the injectable DMD treatment kept 
them from getting worse. 
Regarding the statement, “The injectable DMDs keeps me from getting worse,” 
81% (n = 26) agreed, 13% (n = 4) disagreed, and 6% (n = 2) were uncertain. Almost half 
of the women using (or having used) DMDs (46%; n = 13) reported no change in their 
RRMS symptoms since starting the DMDs, while 36% (n = 10) described their status as 
“better,” and 18% (n  = 5) indicated that their condition was “worse.” Fifty-nine per cent 
(n = 19) of women reported having no relapses over the last year; 25% (n = 8) had one 
relapse, 13% (n = 2) had 2 relapses, and 3 % (n = 1) had five relapses. Three of the 
women who had discontinued DMDs reported experiencing worsening disease despite 
treatment. 
Fifty per cent (n = 16) of women reported that they received information about the 
injectable DMDs from their health care providers; other sources of information were 
websites (38%; n = 12), nurses (9%; n = 3), and books or magazines (3%; n = 1). Most 
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women understood that injectable DMDs ‘prevented or reduced the frequency of 
relapses’ (n = 15), followed by ‘delayed progression’ (n = 10), and ‘prevents new lesions’ 
(n = 7). Women articulated that while they were not a ‘cure,’ they believed the DMDs 
would delay progression and reduce the frequency of relapses, using terms like 
“maintain,” “holding pattern,” “keeping MS at bay,” “slowing it to a crawl,” “stabilizer,” 
and “status quo.” One woman stated, “. . . . and I know that remittent MS can turn into 
progressive. . . . my outlook is if I’m on the medication, I’ll never turn into progressive.” 
Another woman said, “I learned that it’s best to stay on your medicine. . . . it will help 
you stay ahead of it, of getting more attacks. . . . lesions. . . . I don’t want to get worse.” 
However, a woman who discontinued using injectable DMDs described how her 
physician refuted assumptions that the injectable DMDs delayed progression: “She said 
(the effect) is almost anti-inflammatory. . . . it turns it down a little bit but it’s not slowing 
the progression of the disease. . . .” 
Uncertainty 
Uncertainty was a common theme in women’s discussion of their beliefs about 
treatment efficacy. Sixty-four per cent of women using DMDs (n = 16) and 50% of 
women who had discontinued DMDs (n = 3) said they weren’t sure if the medication 
worked. One woman stated, “Do I think it works? I have no idea.” Another woman said, 
“What is it really, really doing?” Furthermore, many women expressed uncertainty 
whether their current stable health was due to the medication’s effects. Three women 
attributed their current condition to having a ‘mild disease.’ However, one woman stated 
that the reason for her stable disease was immaterial: 
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So what changed? Was it the medication? Was it attitude? Was it lifestyle? 
Was it something I’m drinking or eating or breathing? I don’t know. But if 
it’s the medication, good. If it’s got nothing to do with the medication, oh 
well. So I have a few bumps. 
Another woman said, “Is it working? I’m walking and talking, so whether it’s doing 
something or not. . . . I’ll take that chance.” 
Half of the women indicated that they were uncertain about what would happen if 
they were not on the injectable DMDs. When answering the statement on the BMQ, 
“Without the injectable DMD, I would be very ill,” 50% (n = 16) of women were 
uncertain, 31% (n = 10) disagreed, and 19% (n = 6) agreed. One woman professed, “I 
think I wouldn’t feel as good as I do. . . . I THINK. . . . but I don’t know.” Another 
woman who experienced bothersome side effects stated, “On days that I don’t want to do 
Avonex any more, I think nothing would happen. . . . I would be fine and this would be as 
bad as I’d get. . . . so I just don’t know. It’s a crap shoot.” Others stated, “I’m assuming 
it’s helping me,” and, “Well, I haven’t had any flare-ups so I would say it’s better, if the 
medication is working.” One woman felt that if she worsened, it was ‘her own fault,’ not 
the medication. 
Finally, in response to the statement, “My life would be impossible without the 
injectable DMD”, 66% (n = 21) of women disagreed, 19% (n = 6) were uncertain, and 
16% (n = 5) agreed. Two women who had discontinued the DMDs reported their life 
actually became more manageable after stopping. One woman stated, “I felt like I was 
clearer in the thinking. My legs were a little more stiff but I figured I could deal with that 
versus how else I was feeling. I couldn’t eat. . . . couldn’t sleep. . . . I just didn’t like it”. 
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Perceived Concerns 
In the Belief About Medicines framework (Horne & Weiner, 2002), perceived 
concerns are anticipations of unpleasant adverse effects or disruption by a particular 
medication, including long term effects. Concerns may develop from concrete 
experiences with the medication, misinformation, or miscommunication between the 
health care provider and patient. Five statements in the BMQ addressed treatment 
concerns; the results will be integrated with the qualitative data. Concerns regarding the 
injectable DMDs caused some women to either switch or discontinue their treatment. 
Twenty-four percent (n = 5) of women using injectable DMDs switched 
medications; of those, two woman switched twice. The most common reason for 
switching was worsening disease (n = 4), followed by injection site reactions (n = 1), and 
increased liver enzymes (n = 1). All of the women who switched reported improvement 
over the prior DMD. 
Nineteen percent (n = 6) of the women reported discontinuing their injectable 
DMD therapy. Two of the women who discontinued had switched medications; one 
reported switching twice before stopping. Common concerns among the six women who 
discontinued involved both concrete experiences with the DMDs and beliefs about the 
DMD therapy. Concrete experiences included bothersome side effects (n = 4), disruption 
of plans (n = 4), and injection issues (n = 4), fear of needles (n = 2), painful injections (n 
= 1), injection site skin reactions (n = 1), having others inject (n = 1). Concerns related to 
beliefs about the injectable DMDs were perceived mild disease (n = 2), perceived 
worsening disease (n = 2), and uncertainty regarding the effects of the DMDs (n = 1). 
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Necessity-Concerns Differential 
The necessity-concerns differentials were calculated for each participant, and can 
be found in Table 14. Most of the differential scores (n = 24) were positive, indicating 
beliefs in treatment necessity. However, eight differential scores were negative, reflecting 
women’s concerns about treatment. The woman who never started injectable DMDs had 
a negative differential score, as did five of the six women who discontinued DMDs. The 
sixth woman had switched treatment twice due to ineffective DMDs, and then 
discontinued the third injectable DMD due to severe skin site reactions. She stated that 
she did not want to stop treatment. “I tried it for two more weeks. . . . it’s not that I don’t 
want to . . . I can’t. . . . it hurts. . . . it’s not worth it.” Therefore, according to her negative 
differential score, the woman believed treatment was necessary, but her severe skin site 
reactions caused discontinuation. The woman was scheduled to start an intravenous 
treatment. 
Two women who continued using injectable DMDs had negative differential 
scores. One woman expressed doubt about her diagnosis, felt well, and described a 
negative concrete experience with the injectable DMD, including painful injections and 
bothersome side effects. The woman described skipping injections, reducing the dose, 
and considering stopping. Therefore, bothersome side effects while feeling well caused 
more concerns than belief in treatment necessity for the woman. 
The other woman described how she had discontinued treatment on her own once 
before in order to become pregnant, and only resumed due to worsening symptoms. She 
considered the injection “poison” and described “feeling well” off treatment until a bout 
of optic neuritis. The woman stated that she had originally thought she could manage her 
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RRMS without treatment, and even with resuming, was already considering stopping to 
conceive another baby. Therefore, while having more concerns than beliefs in treatment 
necessity, the woman continued with her injectable DMD due to disease worsening while 
off treatment. 
Injection Issues 
Injection issues were problematic side effects of the injectable DMDs. Twenty-
nine percent of women (n = 9) reported having a general dislike of needles. “And even 
after 500 times doing this, every week, once a week, that needle in my leg, I still have a 
hard time with it.” Two women using glatiramer acetate (Copaxone) complained about 
having to undergo daily injections. Anticipation of injections caused emotional distress 
for some women, including “anxiety,” “nervousness,” “agitation,” “anguish,” and 
“dread.” One woman described the anticipation, ‘just the thought of it,’ as ‘hanging 
around in my head’. Specific problems with injections included injection pain (n = 13), 
skin reactions (n = 17), and having others inject (n = 6). 
The injection pain was described as ‘stinging,’ ‘smarting,’ and ‘sore.’ One woman 
explained that the pain was unpredictable. “Some nights it hurts, ‘n some nights it 
doesn’t. You never really know until you hit the injector if it’s going to hurt.” Some 
women indicated that their pain was from the medication rather than the needle. Some 
women (n = 2) described an itchy sensation at the site. Both the interferon and non-
interferon injectable medications caused skin reactions, although painful lumps were 
more common with the non-interferon DMD (glatiramer acetate). The skin reactions 
ranged from mild bruises to hard, painful lumps or sores. One woman discontinued her 
therapy and another woman switched injectable therapy due to severe skin reactions. 
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“But I would always have an injection site reaction, a big, red, hot lump probably 2-3 
inches across that would stay for a long, long time. . . . it was just — it was hard to do it 
every day.” Some women reported having to locate new injection sites due to the residual 
lumps. Most women reported rotating injection sites. 
One woman discussed the impact of her injection skin reactions on her 
relationship with her husband. “He’s afraid to touch me because sometimes I feel 
tingly…or, you know, to touch me where I gave myself a shot because it might be a little 
tender that day. . . . he waits for me to tell him what to do. . . . ” She stressed how 
important it was to her relationship to have him feel like he could physically touch her, 
despite the discomfort it caused. 
Some women described how the injection process took up a lot of their time. 
Women described sitting for minutes or hours, delaying the injection. “I was doing it at 
7:00 every night. . . . I’d be lucky if I shot myself in the leg by 8:30. . . . I just HATE 
doing it.” One woman described her emotional distress during the process. “One day I sat 
here, and I was telling the dog to hit my hands so I wouldn’t have to do it. I mean, I was 
in tears.” The woman ultimately asked others to administer the injection. Many women, 
however, reported that the process eventually took less time. Several women discussed 
the mental preparation that was involved before the injection. A woman whose husband 
was the injector stated, “I try to remind myself. . . . the week before, the needle didn’t 
hurt so bad...it’s not going to hit a bone. . . . then I close my eyes and hold my breath.” 
Taking the injectable DMD on trips or vacation was a concern for some (n = 4), 
and was one of the reasons that one woman discontinued her treatment. “So we went to 
Florida with my daughter. . . . and I didn’t want to take it (IFNB-1b) because it has to be 
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refrigerated and everything. So I just didn’t take it and I haven’t taken it since.” Women 
discussed having to make special arrangements for transporting the IIM during travel and 
vacations. Several women reported packing ice and injection supplies with little 
difficulty; however, other women reported omitting or delaying injections rather than 
carry the DMDs. In fact, the most common reason given for skipping or missing a dose 
was going on vacation. 
Other injection issues involved having others help with injections. While nine 
women self-injected, six women chose to have others give all their injections, and ten 
women self-injected with occasional help. ‘Other-injectors’ included family members, 
friends, or health care providers. Some women had others inject due to their needle 
phobia or to access hard-to-reach locations (arms, hips, buttocks). Sometimes having 
another person inject posed a dilemma for women. One woman said her main injector, 
her daughter, was moving, and she wasn’t sure how she’d manage. Two other women felt 
it was more inconvenient to have others inject because of the planning and travel 
involved. However, one woman who had discontinued her injectable DMDs believed she 
would resume if another person would administer her injections. 
General views about taking medicines influenced some women’s concerns about 
the injectable DMDs. Five women described being reluctant to use the injectable DMDs, 
or any type of medicine at all. One woman who had discontinued the DMD stated, “I’m 
not really into the medication thing. . . . I don’t like what. . . . that kind of drugs do to 
you. . . . I need to stay focused. . . . not be drugged out.” Another woman using DMDs 
described how having to use an injectable DMDs changed her self-concept: “. . . . That 
I’m not infallible. . . . not invincible.” Specific concerns regarding the injectable DMDs 
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included having to plan, insurance issues, lack of active disease, disease worsening, and 
uncertainty related to medication effects. 
When responding to a statement on the BMQ regarding whether the injectable 
DMD disrupted their life, 78% of women (n = 25) disagreed and 22% (n = 7) agreed. 
However, many women reported having to arrange their activities around their injections. 
Depending on the DMD therapy, injections were administered every day, every other 
day, or once a week. The DMDs were refrigerated, and required several hours to warm to 
room temperature. Sometimes women forgot to remove the DMDs from refrigeration, 
and either tried to warm it quickly, or, sometimes, they just skipped the injection. “By the 
time I remember I’m going to take it, you have to wait for it to warm up a little bit and 
then I don’t want to. So I won’t take it.” One woman described how the injectable DMD 
regimen dictated her plans. “I was just at my mother’s house helping her with something. 
. . . I wouldn’t feel comfortable saying, ‘Oh, I think I’ll stay over’, because I don’t have 
my medicine with me. . . . so it makes decisions for you.” 
Only two women described having difficulties with insurance coverage. However, 
both women were able to find alternate means to pay for the medication. One woman 
described the frustration of having to quit her job to be eligible for public assistance 
(MassHealth). Another woman expressed uncertainty about affording the medication due 
to her husband’s retirement. “Because my husband retired…we don’t have no more 
insurance. If I don’t get. . . . the help, I’m not going to do it. I’m not going to pay no 
$1,400 a month.” She was receiving her medication at no cost through one of the 
medication companies, but was not going to continue her DMD without financial 
assistance. 
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Six women indicated that the DMDs had a greater impact on their life than their 
RRMS. Many of these women had few symptoms of RRMS but suffered great discomfort 
from the injectable DMDs. Two women ultimately discontinued DMDs because they ‘felt 
well’ with the RRMS, while at the same time they were experiencing bothersome side 
effects from the DMDs. “It was hard to reconcile in my head. . . . why stress myself out 
like that every other night when I’m really feeling well?” Conversely, a woman who 
continued stated, “Sometimes I feel like I’m taking the medication and I’m not sick 
because I feel so good. . . . now I have come to terms with I’m not sick BECAUSE I’m 
taking the medication. . . .” 
Thirty-two per cent (n = 8) of the women who were currently using injectable 
DMDs reported the onset of new symptoms or new lesions (on MRI). One woman who 
was currently using DMDs described her uncertainty related to the worsening disease; “. . 
. . maybe without the Avonex, I would have ten lesions. . . . it’s a crap shoot.” Another 
woman reported that her new symptoms were mild compared to past symptoms. “My last 
attack was in December. . . . wasn’t as bad as it could be. . . . this time it was just one leg, 
so that was pretty good.” 
However, 33% (n = 2) of the women who discontinued DMDs attributed their 
worsening disease to the injectable DMDs. One woman described having increased 
relapses; another woman reported the increased impairment that severely impacted her 
employment. “I either had three or four (relapses) and I had to go on IV steroids and I 
was pretty much ready to quit work. . . . had to use a cane. . . . I felt like I just couldn’t go 
on.” Both women claimed that their symptoms improved after discontinuing their 
injectable DMDs.  One woman described her improvement, “It’s like being locked in 
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your room for a year and all of a sudden you get out. . . . because I spent a lot of time in 
my bedroom. . . . I was just out cold.” 
Two of the statements on the BMQ addressed concerns regarding immediate and 
long term effects of the injectable DMDs. In addressing the statement, “Having to take 
the injectable DMDs worries me,” 53% (n = 17) of women disagreed, while 47% (n = 15) 
agreed. Furthermore, when responding to the statement, “I sometimes worry about the 
long-term effect of the injectable DMDs,” 59% (n = 19) of women agreed, 34% (n = 11) 
disagreed, and 7% (n = 2) were uncertain. Finally, when answering the statement, “The 
injectable DMD is a mystery to me,” 66% (n = 21) women disagreed, 22% (n = 7) 
agreed, and 12% (n = 4) were uncertain. 
Several women expressed concerns related to the uncertain effects of the 
injectable DMDs. One nurse who discontinued her DMD after only one injection 
described seeing the effect of the DMD on another woman “. . . . I saw one patient (on 
injectable DMD). . . . and really, I didn’t see any changes. . . . as a matter of fact, she was 
getting worse at some points. . . . what is it really, really doing?” Another woman who 
was using an injectable DMD worried that her DMD might be masking worsening 
disease, “. . . . what if I have fifteen more lesions. . . . and I don’t even know it because 
my medication is hiding it. . . . I’d like to have more MRIs. . . .” 
 Addressing the last of the five statements related to treatment concerns, “I 
sometimes worry about becoming dependent on the injectable DMDs,” 88% of women (n 
= 28) disagreed, 3% (n = 1) agreed, and 9% (n = 3) were uncertain. Despite the concerns 
regarding the injectable DMDs, most women expressed a commitment to continue with 
treatment. However, four women reported that they had considered stopping treatment. 
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One woman described being doubtful about her diagnosis, while also suffering severe 
side effects from the DMD. She reasoned that stopping the DMD would improve her 
quality of life. : “I’d rather get. . . . ten good years now than a slow twenty years. . . . I 
only have two. . . . three good days a week, where if I stop, I’ll get my seven. . . . ” 
Another woman described her struggle between wanting to stop and having to 
continue: “I keep doing it and. . . . I don’t know if it’s working . . . the hell with it, I’m 
just not going to do this anymore. . . . but then, when I don’t do it, I say this is stupid. . . . 
you know you have to do this. . . .” One woman wondered how long she would continue: 
“Sometimes I don’t know how many years I’m going to feel like doing this.” Other 
women (n = 4) discussed taking a break from the treatment. But, as one woman said, 
“I’ve definitely asked about taking a break and then going back. . . . but how long do I 
need a break…take a week, a month…I’m not going to tell myself I’m taking the summer 
off. . . . life doesn’t take time off.” 
Motivation: Fear and Hope 
Motivation means “to give a reason or incentive to do 
something”(www.encarta.com). 
Fear and hope were identified by many women as motivators of continuing with 
injectable DMD therapy.  Seven women mentioned that they would not stop their 
injectable DMDs because they feared worsening disease or disability. “When you start 
any treatment that you start for the MS, you have to stick with it. . . . because then your 
fear is that if you don’t, you are going to be in a wheelchair.” Another woman stated, “I 
always thought, OK, I have relapsing-remitting MS. . . . I never thought it could get 
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worse, but yes it can. . . . that scares me. . . . that really gives me the motivation to keep 
the injections going.” 
One woman described being afraid of recurrence of her prior relapse, “I’m in fear 
of what might happen. . . . my left side. . . . just the numbing, burning. . . . my right side 
was weak. . . . I could barely write. . . . couldn’t lift my leg. . . . I just didn’t like the 
feeling at all.” One woman reported having resumed treatment because she had an onset 
of optic neuritis. “When I stopped taking it, I thought, I can live this way...my quality of 
living wouldn’t be degraded that terribly. . . . now having the optic neuritis, that’s a little 
scarier for certain. . . .” 
Fifty-six percent (n = 14) women referred to the injectable DMDs as their only 
hope to control their RRMS. One woman stated, “Knowing that right now this is the only 
hope I have in keeping my disease in remission. . . . I continue regardless of what the side 
effects are.” She spoke of two friends who had died of MS; she felt that, unlike them, she 
was given ‘a gift.’ She believed that, without the therapy, her friends had no hope. Other 
‘hopes’ shared by women were that the DMDs would work, that they could continue with 
the medication, and that an oral medication would soon be available. 
One woman, expressing uncertainty, implied both hope and fear. “Why do I take 
it? Because it might work. . . . you don’t know. . . . but I do it because. . . . I don’t know 
what it would be like if I didn’t do it.” Another woman, when asked about her long term 
plans, said, “. . . . just want to take this journey or this ride for what it is right now until 
something better comes along that offers more hope.” 
Four women described a process of ‘weighing the pros and cons’ in deciding to 
start and continue with their DMDs. One woman described her decision-making process 
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when starting, “There was definitely a little bit of weighing pros and cons. . . . I mean 
there are no guarantees. . . . I chose Rebif.” One woman explained, “Well, I know the flu 
symptoms. . . . and all that. . . . you’ve got to weigh the pros and cons and to me, anything 
you take nowadays has side effects and long term effects, so. . . . ” Another woman 
stated, “I look at it as if it can benefit me more than it can hurt me. . . . that’s why I’m on 
it.” Conversely, one woman who had discontinued after only one injection many years 
ago stated, “What real benefit is it going to be for me? I’ve learned to live with my body 
the way it is now. . . . with my disease the way it is. . . . why start a new treatment now?” 
‘Pros and cons’ described by women are listed in Table 15. 
Two women talked about taking risks with the injectable DMDs. One woman 
said, “It’s a risk. . . . I know life is full of risks, but right now, I’m stable. . . . if that’s the 
price I’m going to pay in my mind, then that’s it.” Another woman stated, “. . . . if it was 
going to maintain me, I do pretty well in between anyway. . . . why take the risk?” Eight 
women professed not wanting to ‘take a chance’ of stopping their DMDs. “I have stayed 
exactly the same. . . . I don’t really know if I would have stayed that way had I not started 
the medicine. . . . I don’t want to take the chance to stop it and see what the end result 
will be.” 
During a re-interview with participants (member checking), one woman described 
her motivation to continue using her DMD as ‘blind faith.’ She felt that she had to have 
faith and hope that her DMD would continue to maintain her in remission and prevent 
progression. However, she said, “It’s a blind faith. . . . you may know what side effects 
you get, but you don’t know if the medication is working. And you have to have blind 
faith that, somehow, you are going to be better.” Another woman described it as ‘the less 
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uncertain road.’ She believed that using the DMD was at least more certain than 
continuing with RRMS without any treatment. 
Aim 3: Examine the influence of health care providers on treatment beliefs and 
management of injectable DMD therapy among adult women with RRMS. 
 Women’s attitudes toward their health care providers were mostly positive. They 
described general characteristics of their health care providers. They also described the 
quality of their interactions with health care providers concerning the initiation, 
continuance, or discontinuation of the injectable DMDs. Finally, they discussed the 
influence of their health care providers on their management of injectable DMD. 
Women described positive characteristics of their health care providers, including 
‘a good listener,’ ‘available,’ ‘easy to talk to,’ ‘doesn’t rush you,’ ‘caring,’ and 
‘compassionate.’  Other women, however, described attributes of their health care 
providers as ‘kind of rushy,’ ‘not talkative,’ and ‘distant.’ 
Women described the availability of their health care providers during and 
between visits. “They’re busy. . . . but not so busy that if I needed to talk. . . . they’re a 
phone call away.” Another woman said “Even though they’re seeing hundreds of 
patients, when they are with you, they make you feel like you’re the only person that they 
have.” One woman said: “They spend the time with you. . . . it’s not like you go in there 
and they go over this list, and you’re there for 15 minutes. . . . and out the door.” 
However, one woman felt that her visit with her health care provider was ‘rushy.’ She 
stated that she tended to avoid asking her health care provider. 
Women described how their health care providers listened, explained, and 
encouraged discussion. Four women reported that their health care providers actively 
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listened. One woman stated, “He absolutely listens to you. . . . listens to what you have to 
say…listens to what your feelings are.” Another woman said of her health care providers, 
“Their compassion and their understanding and their ability to listen…is remarkable for 
as busy a practice that they have.” The woman believed her health care providers’ caring 
and concern were the reasons she continued working with them. However, one woman, 
who did not believe her health care provider understood her concerns, felt that ‘being 
heard’ was essential.  “I think. . . . that the neurologist should LISTEN to the patients. . . . 
and not look at their watch a lot. . . . so that you feel that you’re being heard. . . .” 
Women discussed how their health care provider shared information with them. 
One woman said, “They’re easy to talk to. . . . and they explain everything. . . . answer all 
my questions.” Another woman stated: “If they want to try something different, they’ll 
explain to you. . . . it’s HOW they explain what they want to do for you. . . . it’s the 
overall caring they give you.” She went on, “And they made me having the MS more 
relaxed because they do care. . . . and you know that they are there if you need them. . . .” 
A woman stated, “They act like it really matters.. . . . your input. . . . ” 
However, one woman felt as though her concerns are not always taken seriously. 
“The things that I think are. . . . new things for me or more difficult. . . . or are related to 
MS, he will sort of pooh pooh. . . . ‘that’s not an MS thing’. . . . and I really don’t 
understand.” She reported that she did not share many of her concerns with him. Another 
woman stated she would like her health care provider to ‘see’ beyond the neurological 
disease. “He could be a little bit more. . . . just talking and asking more questions about 
things outside of just the straightforward neurological things.” A woman did not feel her 
health care provider could understand her experience. “He doesn’t feel that I’m getting 
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any worse…but I feel inside like, ‘you don’t know what I’m feeling’. . . . and is not 
understanding how a little thing like your hand being numb can be just devastating some 
days. . . .” 
Three women described having confidence and trust in their health care providers. 
“. . . . And I know my doctor’s on top of things. . . . I know he’d be here to help me and 
to give me any input I needed. . . . that’s a matter of having confidence in my doctor.” 
Another woman said, “I fully trust him and if he says that I need it, then I guess that I 
need it (medication).” One woman stated, “He’s the head of Neurology; he must be a 
good person. . . . so I feel in safe hands.” A woman described her confidence in her 
doctor as equal to her confidence in her injectable DMD. “It’s a combination of having as 
much confidence as I can in the medication but more than that, the healthcare providers 
are. . . . equally important. . . . I just have complete confidence in them.” One woman 
described how her health care providers gave her a sense of control. “when you get to a 
point where don’t feel like you have control of your own body, your own life. . . . and 
there is somebody there that gives you a possible hold or remedy, they’re your best 
friend.” 
Another woman who discontinued her DMD due to severe injection site reactions 
described her confusion after discussing her worsening disease with her health care 
provider “. . . . he went over the medicines. . . . it is supposed to be helping me. . . . the 
radiologist saw significant changes in the MRI. . . . when I talk to him [health care 
provider]. . . . he says there isn’t any. . . . it’s weird.” One woman said of her health care 
provider, “…MS is like an unknown. . . . nobody knows what’s going to happen. . . . I 
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know that he doesn’t either. . . . he’s not God. . . . he doesn’t know what’s going to 
happen next on my MS in particular.” 
Women described how they and their health care providers made decisions 
regarding their general care. Some women said they followed their health care provider’s 
recommendations. One woman stated, “I’m an easy person. . . . I go with what the doctor 
tells me.” Another woman said, “I think I’m a little bit afraid of him [health care 
provider]. . . . he kind of has that scary attitude sometimes. . . . ‘you do as I say’. . . . so 
you do it.” However, two women stated it was important to be partners in their 
healthcare. One woman described a ‘good working relationship’ with her health care 
provider. “He allows me to dictate. . . . he allows me to be a partner in my own 
healthcare.” Another woman stated, “I like to be part of the decision-making. . . . I don’t 
want to be in the situation where I’m told what to do.” 
Women described the initial discussion with their health care provider regarding 
injectable DMD treatment. Eight women reported that their health care provider gave 
them materials to review and to select one of the four injectable DMD. “So he really left 
it up to you. . . . he didn’t recommend one or the other. . . . here’s the pros and cons. . . . 
they leave it up to the patient.” Conversely, seven women reported that their health care 
provider suggested a particular DMD. Six women described doing research on the 
injectable DMD, and preferred to make the decision: “I think it’s definitely a benefit that 
they leave that up to you. . . . it’s your choice. . . . it’s in your hands, but they give you 
enough information to make that decision.” 
Other women wanted help with selecting the ‘right’ DMD. “I would rather say, 
‘here, you take this. . . . because this is a good one’. . . . I’ve chosen the Avonex, but 
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maybe the Rebif is the real good one.” One woman described the uncertainty of choosing 
the right medication. “It was a hard decision for us. . . . what was right. . . . A, B, or C. . . 
. just throw it up in the air. . . . it was like trying to make an educated guess without really 
knowing.” Another woman described the importance of making the decision for herself: 
“It was my decision to start on the medication. . . . my decision which one I decided to go 
with. . . .” 
 Women described the discussion about the management of their injectable DMDs 
during their health visits. Six women reported that they felt they discussed their injectable 
DMDs enough, especially if they had questions or concerns. However, health visits did 
not always include discussion about the injectable DMD. Seven women claimed the topic 
usually did not come up. Many women asserted that their health care provider would 
discuss any problems if they arose. “He’ll ask about any problems. If things are going 
well, we don’t usually talk about it.” One woman stated, “I think they just assume that 
I’m taking it. . . . and it doesn’t like really come up, like, ‘do you take, do you not take 
It’. . . . you know ‘are you taking it faithfully?” Another woman described how her health 
care provider discussed alternative plans in case the treatment didn’t work. “He said if it 
didn’t work. . . . I could try out any one of the other medications. . . . so far, it seems to be 
working. . . . so we are sticking with this one.” 
Women described how their health care providers advised them regarding the use 
of injectable DMDs. One woman who sought a second opinion about her diagnosis 
related her physician’s view regarding when to start using injectable DMDs; “. . . . and 
she wasn’t convinced that I have MS. . . . she was saying it’s one-third of the year. . . . 
that you don’t feel well. . . . she had a difference of opinion when you should start this 
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medicine.” The woman discontinued her DMD in consultation with her health care 
provider. She went on to assert that, if she experienced symptoms, she would consider 
beginning treatment. 
A woman with RRMS for 22 years, who never started injectable DMDs, 
professed a similar experience with her physician: “He said, ‘I will let you know, I don’t 
believe it’s (your RRMS) ready. . . . you don’t have to take it right now. . . .” Another 
woman with mild symptoms who has been using DMDs for 3 years reported that her 
health care provider thought she might be able to discontinue someday. “. . . . the doctor 
said that. . . . if I continue like this, maybe I won’t have to use the medication long-
term…if I don’t have any more attacks after a few years. . . .” 
Women who discontinued injectable DMD therapy described their discussion 
with their health care providers. Of the six women who discontinued DMD therapy, four 
women discontinued without first consulting their health care providers, one woman 
informed her doctor, and one woman stopped in consultation with her health care 
provider. The discussion between the health care providers and women who stopped 
without consultation occurred weeks or months after the women had been off of the 
medication. One woman described her health care provider’s reaction: “He wanted me to 
continue. . . . he was very upset with me at the next appointment because I had just not 
given him the chance to make that decision with me.” She believed their conflict affected 
their rapport: “I called the office. . . . I had some significant pain issues. . . . it was the 
next day when I got called back. . . . (He) and I went toe to toe. . . . so I don’t feel as 
comfortable going to him.” She planned to schedule visits with an associate health care 
provider. 
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Another woman described a more positive experience when her health care 
providers learned she had discontinued treatment. “They asked why I’m not on it and I 
told them. . . . they really didn’t push me that much, not like they were before.” She was 
surprised that their reaction was so mild. She explored alternative treatments with them. 
A woman who discontinued her injectable DMD described feeling understood by 
her health care provider. “She’s compassionate enough to know that I don’t feel 
comfortable being on that med. . . . she would want me to. . . . but she understands.” All 
but one woman who discontinued injectable DMDs have continued regular visits with 
their health care provider. One woman has not seen her health care provider in three 
years. “I haven’t seen him for about three years. Last time I saw him he said, ‘if you have 
a problem, call me’. . . . haven’t had one so I haven’t called.” Another woman who 
discontinued treatment after receiving a second opinion described a positive relationship 
with her health care provider: “I don’t think (he) was happy about it. . . . but he still wants 
to see me. . . . as a matter of fact, he wants to see me more. . . . just so I don’t fall out of 
the loop.” 
Some women reported that, although they received information and support from 
their health care provider, continuing to use the injectable DMDs was still their decision 
to make. One woman stated, “I don’t feel he’s (health care provider) got all the answers 
for what I should be doing, with my MS, and taking Avonex or not.” Another woman 
said, “I don’t think they have any impact at all (on my management of the DMDs). . . . 
when it comes down to it, the decision is mine. . . . I’m the one who decides every week 
that I’m going to do it.” Another woman said, “They can say, oh, make sure you take 
your medicine but I have to make the decision to do it.” One woman described how 
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health care providers should counsel their patients about initiating DMDs. “If they were 
to just explain the benefits of it, to let them know it is their decision.” 
Summary 
In summary, two overarching themes, uncertainty and control, and three related 
subthemes, Bothersome Symptoms/Bothersome Side Effects, Adjusting (limitations, 
changes, strategies, and attitude) and Motivation (fear and hope) emerged from women’s 
descriptions of their experiences managing RRMS. Analysis of the data revealed that, 
whether or not they were using injectable DMDs, most women experienced limitations or 
changes related to their RRMS, including physical, emotional, or relationship transitions. 
Limitations varied depending on bothersome symptoms and uncertainty. Women 
developed strategies to control their bothersome symptoms and maintain an optimum 
level of function. Women also used positive attitudes to cope with the uncertainty, 
limitations, and changes. 
Women’s experiences included a parallel of managing their RRMS and injectable 
DMDs.  While managing their bothersome symptoms, women who were using injectable 
DMDs encountered similar difficulties managing unpredictable and bothersome side 
effects. Some women skipped, switched or discontinued their DMDs due to their 
difficulties, while other women controlled their DMDs through developing strategies and 
having positive attitudes. 
Women also continued or discontinued their injectable DMDs based on treatment 
beliefs, including treatment necessity and treatment concerns. Most women who believed 
that treatment was necessary had stable or improved symptoms or minimal side effects. 
Women who discontinued their DMDs had no symptoms (‘felt well’), had intense side 
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effects, or had worsening disease. However, some women continued with their DMDs 
despite worsening disease or bothersome side effects. Both women who continued and 
discontinued DMD treatment had information and support from their health care 
providers. However, both groups also expressed uncertainty regarding treatment efficacy. 
Women maintained control by making decisions to continue or discontinue their 
injectable DMDs. 
Women weighed the ‘pros and cons’ of the injectable DMDs to decide about 
initiating and continuing treatment. Some women who continued the DMDs expressed 
more benefits, while women who discontinued the DMDs expressed more concerns. 
Women who were uncertain expressed hope in their treatment and fear that stopping 
treatment would worsen their RRMS. They continued using their DMDs with ‘blind 
faith’, uncertain about the treatment effects. Yet, women viewed continuing the DMDs as 
a ‘less uncertain road’ than trying to manage their RRMS without treatment. This study 
highlighted the experiences of women with RRMS who were using or not using 
injectable DMDs, including day-to-day management, treatment beliefs, and health care 
provider influence. Awareness of these unique issues is important when planning 
strategies to educate, counsel, and support women with RRMS. 
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Chapter V 
Discussion 
The purpose of this study was to gain an understanding of women’s experiences 
of managing RRMS, including using injectable DMDs. This topic was important because 
few studies have examined the parallel experience of managing RRMS and injectable 
DMDs. Findings from the descriptive summaries revealed that women experienced 
unique changes and limitations related to their RRMS; however, women adjusted through 
maintaining a positive attitude and developing strategies to manage their bothersome 
symptoms. Similarly, women adjusted to their DMDs through a positive attitude and 
developing strategies to manage bothersome side effects. Treatment adherence was 
influenced by women’s parallel RRMS/DMDs experience, women’s treatment beliefs, 
and health care provider influence. 
Uncertainty and control were important components of the parallel experience, 
and influenced women’s beliefs. Health care providers offered information and support; 
yet, women were uncertain about treatment efficacy and long-term effects. Despite the 
uncertainty, most women continued treatment, while others discontinued their injectable 
DMDs. Hope and fear were perceived as motivators of continued treatment. This chapter 
will address current findings and existing literature related to uncertainty, treatment 
beliefs, and health care provider influence. 
Uncertainty 
Mishel (1988) defined uncertainty in illness as “the inability to determine the 
meaning of illness-related events [that] occur in situations where the decision-maker is 
unable to assign definite values to objects and events, and/or is unable to accurately 
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predict outcomes because sufficient cues are lacking” (p. 256). Mishel’s Uncertainty in 
Illness model (1988) was derived from Lazarus and Folkman’s (1984) work on stress, 
appraisal and coping. Mishel’s models of Uncertainty in Illness (1988, 1990, 1997, 1999) 
are commonly used in nursing research and practice. 
According to the Uncertainty in Illness model (1988, 1990) uncertainty is an 
inherent aspect of chronic illnesses such as RRMS. Factors that may cause or exacerbate 
uncertainty in chronic illnesses include ambiguity regarding the illness, complexity of 
treatment and care, inconsistent information from authority figures, and unpredictability 
of the illness course or outcome (Mishel, 1988). Adaptation is largely dependent on 
personal attributes, social supports, and appraisal of the uncertainty (as a danger or an 
opportunity). 
Mishel (1988) suggested that individuals who identify uncertainty as a danger 
may attempt to reduce uncertainty through information-seeking, vigilance, and garnering 
social support. On the other hand, perceiving uncertainty as an opportunity may cause 
some individuals to control, rather than reduce, uncertainty through maintaining a sense 
of hope. Uncertainty may allow some individuals to maintain a sense of hope in illness 
conditions that might otherwise evoke helplessness or hopelessness. Mishel (1988) 
suggested that, under these circumstances, maintaining uncertainty may yield more 
positive outcomes, such as adherence to treatment or medications. Controlling 
uncertainty involves focusing on positive cues (information, comparison to others, 
improvement in health status) and prioritizing one’s life. 
Mishel’s framework is effective in explaining women’s experiences in this study. 
Women described a pervasive uncertainty in living with and adjusting to RRMS and 
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injectable DMDs. Uncertainty encompassed unpredictable bothersome symptoms and 
treatment side effects, relapses, daily functional status, disease worsening, and future 
outlook. Women’s adjustment to their RRMS varied, with most women indicating that 
‘you just live with it’ and ‘you learn to deal with it’.  Some women described a constant 
mindfulness of or vigilance over their condition, while others indicated that they never 
thought about their illness until their DMD injection day. All of the women described 
ways in which they had incorporated the RRMS into their lives. Women controlled their 
RRMS by developing strategies to manage their bothersome symptoms and avoid 
relapses. Some women made plans for advanced education, early retirement, travel, and 
vacations. 
These findings are consistent with others related to RRMS found in the literature 
(Courts, Buchanan, & Werstlein, 2004; Jopson & Moss-Morris, 2003; Kroencke, 
Denney, & Lynch, 2001; Miller, 1997; Vaughan et al., 2003). Although published a 
decade ago, Miller’s (1997) study revealed that individuals’ adjustment to RRMS 
mirrored the adjustment experienced by the women in this study. Participants described 
experiencing a sense of loss of control due to uncertain symptoms and relapses, and 
regaining control through maintaining a positive attitude and developing strategies. 
Miller (1997) suggested that individuals who had adjusted well had learned to control 
their symptoms and maintained a sense of optimism. It was unclear whether these 
individuals were using injectable DMDs. 
More recently, Thorne and colleagues (2004) found that patients’ (with MS, non-
specified) fear due to illness uncertainty was initially managed through seeking 
information from external sources, including health care providers, Internet resources, 
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and MS support agencies. However, patients subsequently described adjusting to their 
illness by re-ordering priorities and developing effective management strategies. They 
perceived that ongoing support with information from health care providers was essential 
as they managed their changing functional abilities, difficult or unpredictable symptoms, 
and optimization of their health. Other findings related to uncertainty, perceived control, 
and adjustments were reported in the literature (Courts et al., 2004; Jopson & Moss-
Morris, 2003; Kroencke et al., 2001, Russell, Kilburn, Conn, Libbus, & Ashbaugh, 2003; 
Vaughan et al., 2003). 
 It is conceivable that perceiving uncertainty as an opportunity motivated some 
women to initiate and continue use of injectable DMDs. Some women described having a 
sense of control in undergoing treatment with injectable DMDs. Verheggen and 
colleagues (1998) found that individuals (N = 52) facing uncertainty were more apt to 
agree to participate in a clinical trial. However, uncertainty can also negatively influence 
patients’ adjustment and subsequent behavior. Wineman and colleagues (2003) found 
that patients with greater uncertainty and greater disability were likely to be less hopeful 
and experience negative adjustment to their RRMS. 
In summary, Mishel’s Illness Uncertainty model explained women’s experiences 
in this study. Women managed uncertainty through developing strategies, re-ordering 
priorities, and maintaining a positive attitude. Uncertainty caused women to seek 
information from health care providers and other sources. Finally, women perceived 
uncertainty as an opportunity and sustained hope for the future and hope in the injectable 
DMDs. 
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Beliefs About the DMDs 
 The Belief About Medicines framework (Horne, 1997), suggested that 1) 
patients’ behaviors regarding medicines were influenced by their beliefs, including 
treatment necessity and treatment concerns; 2) a predominance of one belief over the 
other would predict behavior; and 3) patients engage in constant monitoring of their 
treatment beliefs, and their behavior changes with changing beliefs. Treatment beliefs are 
based on general beliefs held about medicines, concrete experience with the medications, 
and information from others, including health care providers. The BMQ elicits treatment 
beliefs, and its necessity-concerns differential determines the predominance of one set of 
beliefs over the other. 
Treatment Necessity 
The Beliefs about Medicines framework explained the behavior for most of the 
women in this study. Qualitative data was congruent with the quantitative results of the 
BMQ. The findings suggest that most women were ambivalent about treatment 
effectiveness. The majority of women agreed that the injectable DMDs improved their 
present and long term health. Perceptions of treatment necessity were regarding stable 
health, decreased relapses or symptoms, feeling in control, and having a sense of hope. 
Women based their positive beliefs on symptom experience as well as information from 
health care providers, Internet sites, and reading materials, such as magazines. 
However, fifty percent of women were uncertain whether they would be very ill 
without treatment. Almost half of the women in the study reported no change in their 
symptoms while on treatment. Moreover, forty-one percent of women reported having 
one or more relapses over the last year. Therefore, women were unsure whether the 
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injectable DMDs were instrumental in stabilizing their RRMS. While not a cure, DMD 
treatment is modestly effective (30%) in reducing the frequency of relapses. However, 
residual symptoms and even new symptoms can persist despite adherence (Calabresi, 
2002). Patients may need reassurance that even without obvious signs, the injectable 
DMDs are working to minimize neuroinflammatory damage. 
Women (66%) disagreed that their lives would be impossible without the 
injectable DMDs. These women may have experienced stable health without 
improvement, worsening health, or unpleasant effects from the injectable DMDs. Several 
women reported that their quality of life improved after they discontinued treatment. 
Assessing patients’ experiences and beliefs regarding their injectable DMDs is important 
in order to develop informational and support strategies. 
Treatment Concerns 
Six women discontinued injectable DMDs in this study. Treatment 
discontinuation ranged from 1 week to 2 years, consistent with the literature (Ruggieri et 
al., 2003). Type of injectable DMD was not a factor in discontinuing treatment, as has 
been suggested in the literature (NARCOMS News, 1999; Ruggieri et al., 2003). Two 
women discontinued IFNB beta-1a IM, two women discontinued IFNB beta-1b, and two 
women discontinued glatiramer acetate. The adverse effects were not specific to an 
injectable DMD. For example, bothersome side effects were caused by IFNB beta-1a IM 
and IFNB beta-1b; worsening disease was caused by Interferon beta-1a and glatiramer 
acetate. 
Five of the six women who discontinued using the injectable DMDs had a 
negative necessity-concerns differential score, indicating more concerns than treatment 
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necessity. The sixth woman, who had discontinued her DMD due to severe skin injection 
site reactions, had a positive necessity-concerns differential score. She felt that treatment 
was still necessary despite overwhelming injection issues. The woman was prescribed an 
intravenous infusion treatment, consistent with treatment guidelines (National Multiple 
Sclerosis Society, 2005). Discontinuing treatment in this study is consistent with 
adherence behavior described by Meichenbaum and Turk (1987). Deliberate non-
adherence may result from a decision by individuals to maintain control of and improve 
their quality of life. 
An interesting finding was that two women who were using the injectable DMDs 
had negative scores, indicating stronger beliefs regarding treatment concerns over 
treatment necessity. One of the women had expressed doubt in her diagnosis, had 
described painful injections and severe side effects, had skipped or reduced the dose, and 
was considering stopping treatment. The other woman had stopped for a year due to a 
pregnancy, and decided to stay off treatment because she had few symptoms. However, 
due to a sudden bout of optic neuritis, she contacted her health care provider and resumed 
the DMD. Although she is currently using her DMD, she still reported treatment 
concerns, and was considering stopping to have another baby. This behavior is consistent 
with other studies (Horne & Weinman, 1999; Horne et al., 1999; Hunot, Horne, Leese, & 
Churchill, 2007; Neame & Hammond, 2005; Ross et al., 2004). Patients with negative 
necessity-concerns differential should be considered at greater risk for discontinuing 
treatment, and should be given continuous information and support. 
Treatment concerns included injection issues, side effects, treatment cost, and 
uncertainty about treatment efficacy. Women’s descriptions of injection issues were 
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consistent with the literature (Harris et al., 2005/2006; Nicholl, 2002). Women switched 
or discontinued treatment due to injection site reactions. Other concerns voiced were 
having others inject, fear of needles, and painful injections. It is possible that injection 
anxiety or fear might be reduced with training, support, and injection equipment (Cox & 
Stone, 2006). Moreover, reducing injection pain with pharmacological and 
nonpharmacological strategies may improve injection experiences (Denis et al., 2004). 
Side effect profiles reported by the women in this study were also consistent with 
the literature (Holther & Hohlfield, 1999). Women controlled bothersome side effects 
through developing strategies and through skipping or switching medications. One 
woman discontinued after one injection due to intolerance of side effects. Women’s side 
effects decreased over time, similar to other findings (Jacobs, et al., 1996; The IFNB 
Study Group, 1993; The PRISMS Study Group, 1998). Education and support regarding 
strategies to minimize or control side effects may be helpful to patients with RRMS. 
Cost of the DMDs was not perceived as a barrier to treatment in this study. 
However, one woman described having to quit her job to be eligible for state-
administered insurance, while another woman utilized a drug company’s foundation to 
temporarily subsidize her treatment. Both women expressed uncertainty regarding being 
able to afford treatment.  Insurance issues can represent barriers to treatment for patients 
Health care providers may be helpful in advocating for patients with insurance companies 
or drug company programs. 
Uncertainty influenced treatment concerns in this study. Uncertainty was related 
to unpredictable and bothersome side effects, disease worsening, and questions about 
treatment efficacy. Four women discontinued use of the injectable DMDs for perceived 
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lack of active disease or disease worsening while on treatment, consistent with prior 
studies (Daugherty et al., 2005; Onesti, et al., 2003; O’Rourke & Hutchinson, 2005; Rio, 
et al., 2005; Ruggieri, et al., 2003; Tremlett & Oger, 2003). Calabresi (2002) suggested 
that new symptoms may mislead women to confuse treatment side effects with worsening 
disease. Accurate information and support regarding new symptoms may prevent 
premature stopping of treatment. 
Women’s beliefs were fairly evenly divided in their response to “worries about 
the injectable DMDs” on the BMQ. More specifically, fifty-nine percent of women were 
worried about the long-term effects of the medications. Although 66% of women 
indicated that the DMDs “were not a mystery” to them, women’s concerns may be 
related their lack of knowledge about the long-term effects. More long-term studies are 
needed. 
Weighing the Pros and Cons 
 Women in this study described a process of ‘pros and cons’, of balancing their 
perceived treatment benefits against concerns. This finding is congruent with the ‘cost-
benefit analysis’ described in the Beliefs About Medicines framework (Horne and 
Weinman, 1999). Weighing the ‘pros and cons’ is a continuous process that begins at 
initiation of treatment and varies among and within individuals (Johnson et al., 2006). 
Changes in beliefs due to concrete experiences, information, support, or personal control 
may influence treatment continuation. Due to the uncertainty of the treatment effects, 
women in this study who continued to use the injectable DMDs identified hope and fear 
as motivators for continuing treatment. 
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Hope and Fear 
Women described hope in their treatment and a sense of control not only with, but 
over, their treatment. Although they were aware that injectable DMDs did not provide a 
cure, women described hope in reducing symptoms or reducing the number and intensity 
of relapses. Women also expressed hope for a cure, and for a pill form of treatment. 
 Fear was expressed by women in terms of uncertainty of the future and 
consequences of discontinuing the injectable DMDs. Women described not wanting to 
‘take a chance’ of stopping treatment for fear that their symptoms or relapses would 
recur. One woman indicated that her fear of having another serious relapse compelled her 
to continue her injectable DMD. Therefore, fear was a strong motivator for continuing 
injectable DMDs. Fear was also expressed regarding injection pain, needle phobia, 
injection site reactions, and bothersome side effects. Fear and hope were not depicted in 
the Beliefs About Medicines framework; however these concepts may be unique to 
complex and difficult treatments, such as injectable DMDs. 
These findings are similar to recent studies involving injectable DMDs.  Miller 
and Jezewski (2001) conducted a phenomenological study among patients with RRMS (N 
= 20) who were using interferon beta-1a IM. Patients mentioned having a sense of control 
with the DMDs to cope with the uncertainty.  The experience of managing their 
injectable DMDs included hope in the DMD as well as hope for a disability-free future. 
Patients also described fear of needles, injection issues, and cost of treatment. There was 
no mention of fear of consequences with stopping treatment. Other studies have 
examined hope and medication use (Fraser, Hadjimichael, & Vollmer, 2001; Fraser, 
Morgante, Hadjimichael, & Vollmer, 2004; Lindstrom et al., 2006; Verheggen et al., 
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1998). Fraser and colleagues (2001) found that hope was significantly related to 
medication adherence (p = .03) in patients with MS who were using injectable DMDs (N 
= 341). 
Thorne and colleagues (2004) described ‘’fear points” (p18) experienced by 
patients throughout their illness course of MS. Patients experienced periods of heightened 
uncertainty and fear from prediagnosis through postdiagnosis and negotiating the illness. 
Use of injectable DMDs was not included in that study. Twenty-eight percent of women 
in this study specifically described continuing treatment out of fear of recurring relapses 
and disease progression. Yet, many women described fear of needles, injections, and side 
effects of treatment. The paradox of fear of treatment and fear without treatment has not 
been well addressed in the literature, and deserves further study. 
Johnson and colleagues (2006) conducted a phenomenological study of patients’ 
perspectives of their injectable DMDs (N = 18). Patients described a decision-making 
process of weighing the pros and cons of treatment. Participants continued with their 
DMD due to the perceived benefits (fewer relapses, more stable illness course, perceived 
control); however, they also described concerns related to the treatment, including cost, 
fear of injections, denial of disease, and uncertainty related to treatment effect).  While 
there was no mention of fear motivating continuing treatment, patients did indicate that 
they did not want to take a chance of stopping. Those who discontinued or chose not to 
undergo treatment reported that they did not believe that they were ‘sick enough’; in 
addition, they attributed non-use of the DMD to fear of side effects, needle phobia, cost, 
and physician advice. Patients reported that physicians advised them that their illness was 
‘stable’ and did not require treatment at that time. 
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The present study supported Johnson and colleagues’ (2006) findings. Patients 
engage in an ongoing appraisal of their treatment beliefs through concrete experiences, 
information, and feelings of personal control. The added value of this study is the use of 
the Beliefs About Medicines framework, which provided a conceptual underpinning for 
decision-making concerning a complex and difficult treatment. 
In summary, the Beliefs About Medicines framework explained women’s 
experiences in this study. The BMQ provided quantitative validation of women’s 
subjective responses. Women’s concrete experience with side effects, worsening disease, 
and lack of disease activity influenced their treatment concerns and adherence behavior. 
Women weighed the ‘pros and cons’ of treatment on an ongoing basis. Fear and hope 
were not explained by the Beliefs About Medicines framework. Fear and hope motivated 
treatment continuation with injectable DMDs. 
Health Care Provider Influence 
 All of the women in this study were treated by a neurologist or an MS specialist, 
similar to estimates of MS patients found in the literature (Vickrey et al., 1999). Access 
to skilled and knowledgeable professionals is essential to patients with RRMS. Patients 
treated by a neurologist are more likely to be prescribed the most current treatments. 
Women in this study reported positive attitudes toward their health care providers. 
Important health care provider characteristics, including expertise in RRMS, attentive 
listening, information-giving, caring attitude, and openness to shared decision-making 
were identified. 
Attentive listening was described as an important attribute in health care 
providers. Women reported that ‘being heard’ by their health care provider was essential. 
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However, several women described how their health care providers dismissed their 
concerns regarding new or worsening symptoms. Paterson (2001) found that health care 
providers minimized or dismissed patients’ experiences, leading patients to avoid sharing 
information or even lie about their health behaviors. This practice can lead to a mistrust 
and lack of confidence between the health care provider and patient (Thorne et al., 2004). 
Uncertainty with RRMS and the injectable DMDs makes it imperative that 
information is current, relevant, and readily accessible (Thorne et al., 2004). Uncertainty 
compels information-seeking among patients (Mishel, 1988). Women in this study 
reported getting most of their information from their health care provider, followed by 
Internet sites and magazines. All of the women indicated that, although busy, their health 
care providers were available during health visits and by phone. Women reported that 
information was effectively explained. Kendrew and colleagues (2001) found that 
satisfaction with information about medications fostered adherence among patients. 
Therefore, satisfaction with information regarding injectable DMDs may explain 
women’s adherence to their treatment. 
However, some women felt that communication during their health care visit did 
not include the affect of the illness and treatment on their personal life. Therefore, they 
felt that they were not given sufficient information and support. Patients have expressed a 
desire to have information that is tailored to their unique needs (Somerset, Campbell, 
Sharp, & Peters, 2001). Health care providers need to ask questions that encourage 
patients to share relevant information regarding the impact RRMS and the injectable 
DMDs have made on their life (Thorne et al., 2004). 
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The unique issues related to RRMS and the injectable DMDs require 
collaborative decision-making during the initial discussion regarding treatment. 
Uncertainty about the treatment may compel some patients to take an active role in 
shared decision-making (Heesen et al., 2004; Kasper, Kopke, Mulhauser, & Heesen, 
2006). Many women in the study indicated a preference to participate in shared decision-
making during initiation of treatment. However, Zwibel (2003) found that patients made 
treatment decisions alone approximately 40% of the time. Many women said they were 
given materials to review by their health care provider and told to select a DMD. These 
women spent extensive time researching treatment choices and were pleased to make 
their own decision. However, some women preferred to be advised on treatment options. 
They were concerned that they did not select the most effective treatment. It is important 
to determine the patients’ level of participative decision-making (Denis et al., 2004). In 
addition, additional time spent providing information specific to each DMD may increase 
patients’ confidence in decisionmaking.  
Several women in the study reported discontinuing their injectable DMDs without 
consulting their health care provider, as described in the literature (Stickel, 2005). 
Women reported that they discontinued treatment to improve their quality of life. Janse 
and colleagues (2004) found that differing perceptions of quality of life between patients 
and health care providers may adversely affect treatment adherence. Health care 
providers may value injectable DMDs for their (modest) efficacy, while patients may 
resist treatment due to the bothersome side effects or treatment inefficacy. Approximately 
one-third of the women reported that the subject of adherence to or problems with 
injectable DMDs was not addressed during health visits. Thus, ongoing communication is 
  108  
imperative to discern concerns, questions, or changes in adherence behavior (Bultman & 
Svarstad, 2000; Denis et al., 2004). 
Despite discontinuing their injectable DMDs, most women felt supported by their 
health care providers. They continued to be monitored with regularly scheduled health 
visits. One woman reported that her last health visit was several years ago. Her health 
care provider instructed her to return if she ‘had any problems’.  Given the uncertainty of 
the RRMS illness course, and ongoing subclinical damage, patients who are not 
experiencing active disease may be misinformed about the importance of regular health 
visits. Health care providers should reinforce appropriate treatment recommendations, 
including regular health visits. 
Two women in the study were advised not to use injectable DMDs by their health 
care providers. One woman never started, while another discontinued treatment after a 
year. This finding is supported in the literature (Holland et al., 2001; Pittock et al., 2006). 
Some physicians are electing, with their patients, to take a ‘watch and wait’ attitude, and 
delaying treatment until signs of active disease. This practice runs counter to current 
treatment guidelines that recommend immediate and sustained treatment for all patients 
with RRMS. Uncertainty regarding adherence to treatment guidelines can lead to 
confusion and increased anxiety for the patient. Health care providers must provide 
timely and accurate information, monitoring, and support to ensure optimal treatment for 
these patients. 
 The presence of fear and hope in women who are continuing their treatment 
should be explored by health care providers. Women maintain a continual process of 
weighing the pros and cons of their injectable DMDs; yet, many times they deliberately 
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ignore, control, or tolerate bothersome treatment effects because of their beliefs in 
treatment necessity. Fear of treatment and fear without treatment constitute a powerful 
paradox for patients. Women in this study described how they refrained from asking 
questions or sharing information at their health care visits. Thorne and colleagues (2004) 
found that communication that was ongoing, accurate, up-to-date, and patient-centered, 
help patients manage fear related to their MS. Conversely, insufficient or withheld 
information, technical jargon, delayed appointments and lack of empathy heightens fear 
and uncertainty in patients. It is conceivable that health care communication that focuses 
on patients’ experiences, beliefs, concerns, hopes, and fears concerning the injectable 
DMDs may foster better understanding and improved collaboration among patients and 
health care providers in managing RRMS. 
 In summary, information and support are essential for patients who are managing 
their RRMS and injectable DMDs. Furthermore, attentive listening and discerning 
relevant psychosocial information may assist health care providers to meet the unique 
needs of patients. Collaborative decision-making during initiation and ongoing treatment 
may ensure understanding of patients’ changing symptom experience or beliefs that 
hamper adherence. Finally, clarity about treatment guidelines, including regular health 
visits, may improve patients’ management of their RRMS, and improve quality of life. 
Limitations 
There are several limitations in this study. First, this is a cross-sectional study, 
using a one-time interview to explore adherence behaviors and beliefs among women 
with RRMS who are using injectable DMDs. The small sample size limits 
generalizability to the larger population of women with RRMS who are using injectable 
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DMDs. The majority of participants in this study were recruited from a central 
Massachusetts MS clinic or neurology practice. Their experiences may not reflect 
experiences of women who are treated by general practice physician or in other areas. 
Further, women self-selected to participate in this study. They may not share the same 
experience as women who chose not to participate. Finally, the order of data collection 
may have influenced women’s responses. Women were interviewed with qualitative 
questions first, followed by the BMQ instrument. The interview questions related to 
women’s beliefs may have influenced women’s responses on the BMQ. 
Implications for Research 
This study added knowledge regarding women’s parallel experiences of managing 
RRMS and injectable DMDs, including adherence behaviors, women’s beliefs about the 
DMDs, and health care provider influence on illness and treatment management. Further 
study is appropriate in several areas. A study of women’s adherence behaviors and beliefs 
over time is needed to anticipate factors that may adversely affect management of 
injectable DMDs. In addition, expanded use of the BMQ among a larger sample of 
participants is necessary to validate the preliminary findings in this study. A study of 
men’s experiences and beliefs regarding injectable DMDs is important, as their 
perspective may differ from women. Finally, a study on the effect of communication 
techniques on patients’ adherence to the injectable DMDs may improve health care 
provider-patient relationships, and result in better management of RRMS. 
Implications for Practice 
The findings in this study identify communication as a powerful tool in managing 
uncertainty among patients with RRMS. Health care providers must give patients 
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ongoing, accurate, and timely information; in addition, health care providers must discern 
the psychosocial as well as the physical and emotional impact of RRMS and the 
injectable DMDs. Women in this study continued with their injectable DMDs despite 
barriers to treatment. However, they exhibited uncertainty regarding treatment benefit as 
well as concerns about the long-term effects of the DMDs. Health care providers must 
assess patients’ concrete experience and beliefs at every health care visit in order to 
provide relevant and patient-specific information and support. 
Nurses play an integral role in educating and supporting patients as they manage 
their RRMS. Nurses spend time with patients within and between visits. Information and 
support through in-person and telephone counseling by nurses can help patients to 
manage uncertainty, share concerns, and identify barriers to treatment. Nurses can also 
refer patients to resources that increase their knowledge and understanding about RRMS 
and injectable DMDs. Finally, by evaluating the psychosocial impact of RRMS and 
injectable DMDs on patients’ lives, nurses can implement more patient-centered 
interventions that may improve management of RRMS and injectable DMDs. 
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Table 1. Types and Prevalence of MS 
 
Relapsing-Remitting (RRMS) (85%) — acute, self-limited episodes of neurologic 
dysfunction that develop over days and weeks, with partial or complete recovery over 
weeks to months. 
Secondary-Progressive (SPMS) — begins as RRMS; as disease progresses, relapses 
decline and are replaced by slow, steady progression. 
50% with RRMS have SPMS in 10 years; 90% with RRMS have SPMS in 25 years. 
Primary-Progressive (PPMS) (10%) — Gradual, steady deterioration without 
superimposed relapses. 
Progressive-Relapsing (5%) — Continuous disease progression with occasional 
superimposed relapses. 
Source: Lublin, F.D. & Reingold, S.C. (1996). Neurology, 46, 907-911. 
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Table 2. Kurtzke Disability Status Scale 
0.0= Normal neurological exam; 
1.0= No disability, minimal signs in one (Function system) (FS)*; 
1.5= No disability, minimal signs in more than one FS; 
2.0= Minimal disability in one FS; 
2.5= Minimal disability in more than one FS; 
3.0= Fully ambulatory; moderate disability in one FS, or moderate disability in 3-4 FS; 
3.5= Fully ambulatory; moderate disability in one FS; 
4.0= Fully ambulatory; self-sufficient; up and about 12 hours even with severe disability;  
            able to walk 500 meters without aid or rest; 
4.5= Fully ambulatory; self-sufficient; may require minimal assistance; relatively severe  
            severe disability; able to walk 300 meters without aid or rest; 
5.0= Ambulatory to 200 meters without aid or rest; disability severe enough to impair    
            daily activities (e.g., work); 
5.5= Ambulatory to 100 meters without aid or rest; disability severe enough to preclude  
             full daily activities; 
6.0= Intermittent or unilateral constant assistance (cane, crutch, or braces) required to  
             walk 20 meters without resting; 
6.5= Constant bilateral assistance (cane, crutches, brace) required to walk 100 meters  
              with or without resting; 
7.0= Unable to walk beyond 5 meters even with aid; essentially restricted to wheelchair;  
             wheels self in standard wheelchair and transfers alone; up in wheelchair 12 hours  
              a day; 
7.5= Unable to take more than a few steps; restricted to wheelchair; may need aid in  
              transfer; wheels self but carry on in a standard wheelchair a full day; may require 
              a motorized wheelchair; 
8.0= Essentially restricted to bed or chair or perambulated in wheelchair; but may be out  
              of bed much of the day; retains many self-care functions; generally has effective  
              use of arms; 
8.5= Essentially restricted to be much of the day; has some effective use of arm(s);  
              retains some self-care functions; 
9.0= Helpless bed patient; can communicate and eat; 
9.5= Totally helpless bed patient; unable to communicate effectively or eat/swallow; 
10.0= Death due to MS. 
 
Source: Kurtzke, J.F. (1983). Neurology, 33, 1444-1452. 
 
 Note: Functional Systems (FS) are eight scales representing different functions of the 
CNS (Kurtzke, 1961). Each system is rated on a five-point (three systems) or six-point 
(four systems) response scales except ‘Other Functions’ which is rated dichotomously 
(0=none, 1=any other neurological findings attributed to multiple sclerosis).  
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Table 3. Immunomodulatory Agents for RRMS 
Type Interferon Beta-
1a  IM  
(Avonex) 
Interferon Beta-
1a SC  
(Rebif) 
Interferon Beta-
1b SC 
(Betaseron) 
Glatiramer 
Acetate 
(Copaxone) 
Manufacturer Biogen Ares-Serono Berlex Teva Marion 
Partners 
Approved in 
US 
1996  1993 1996 
Cost* 
(Wholesale) 
$16,608 $20,553 $17, 827 $16,026 
Dosage; route; 
Frequency  
30 mcg (6MIU) 
IM/ Weekly  
22 or 44 mcg (6 
or 12 MIU) SC/ 
3 times/week 
250 mcg 
(8MIU) SC/ 
Every other day 
20 mg SC/ 
Daily  
Common Side 
Effects+ 
Increased 
depression, 
suicidal 
ideation, new or 
worsening 
psychiatric 
disorders; flu-
like symptom 
complex; 
headache; 
paresthesia; 
hypertonia; 
myasthenia; 
pain; myalgia 
Increased 
depression, 
suicidal 
ideation, 
suicide 
attempts, new 
or worsening 
psychiatric 
disorders; flu-
like symptom 
complex; 
headache; 
injection-site 
reaction; 
abnormal liver 
function tests; 
leukopenia; 
myalgia; back 
pain 
Use with 
caution with 
depression; flu-
like symptom 
complex; 
lymphopenia; 
injection-site 
reactions; 
asthenia; 
hypertonia; 
headache; pain; 
injection-site 
necrosis (5%);  
Injection site 
reactions; 
vasodilatation; 
chest pain; 
asthenia; 
infection; pain; 
nausea; 
arthralgia; 
anxiety; 
hypertonia; 
Post-injection 
pseudo-
anaphylaxis 
symptom 
complex  (10%)
 
*Source: National Multiple Sclerosis Society. Available at:  
http://www.nationalmssociety.org/Research-TysabriQ&A.asp.  
+ Source:  
Avonex:  Data on file. Biogen IDEC, 2005. Available at http://www.avonex.com.  
  Rebif: Data on file. Serono, Inc. 2004. Available at http://www.rebif.com.  
 Betaseron: Data on file. Berlex Laboratories, 2003. Available at 
http://www.berlex.com/html/products/pi/Betaseron_Medication_Guide.pdf.  
Copaxone: Data on file. Teva Neuroscience, 2004. Available at 
http://www.mswatch.com/ContentRoot/miscellaneous/pdfs/PI_Copp0204HW_Oct04.pdf.  
 
 
  143  
Table 4. Efficacy Profiles Demonstrated by Phase III, 2-year Clinical Trials 
 
Type IFNB-1a IM 
 
Avonex 
IFNB-1a SC 
 
Rebif 
IFNB-1b 
 
Betaseron 
Glatiramer 
Acetate  
Copaxone 
Phase III Study  Jacobs et al, 
1996 
PRISMS Study 
Group, 1998 
The IFNB MS 
Group, 1993 
Johnson et al, 
1995 
Pt. Population 
(med; placebo) 
N=301;  
(158; 143) 
N=560 
(189/184; 187) 
N=372 
(125/124; 123) 
N=251 
(125;126) 
Dosage 
 
30 mcg IM 
weekly (n=158) 
22mcg 3x/week 
(n=189); 44 
mcg 3x/week 
(n=184) 
1.6 MIU every 
other day (n= 
125); 8MIU 
every other day 
(n=124) 
30 mg every 
day (n=125) 
Endpoints Primary: 8 
Secondary: 
1,2,4,6, 9 
Primary: 9, 10 
Secondary: 2-4, 
6,8   
Primary: 1,2 
Secondary: 3-7 
 
Reduced 
Relapse Rate* 
32%  
(p= .002) 
27% (22 mcg)  
(p< .005); 
33% (44 mcg) 
(p< .005) 
34% (8MIU) 
(p= .0001) 
29%  
(p= .007) 
Sustained 
Disability* 
37%  
(p=.02) 
22% (22 mcg) 
(p= .04); 
30% (44 mcg) 
(p= .01) 
29% (NS) No difference 
Decreased 
number Gd + 
lesions** 
89% (2y) 
(p= .003) 
84% (2y) 
(p< .0001) 
83%  
(p=.0089) 
29% (9 mo) 
(p= .003 
Decrease in T2 
lesions 
91% (18 mo) 
(p= .001) 
67% (22 mcg) 
78% (44 mcg) 
(p< .0001) 
75% (2y) 
(p= .0026) 
30% (9 mo) 
(p= .003) 
Decrease in T1 
black holes*** 
68% (2y) 
(NS) 
No data No data 37% (9 mo) 
(NS) 
Decrease in 
brain atrophy 
55%  (2y) 
(p= .03) 
 
No data No data 2.5% (18 mo) 
(p= .037) 
 
Note: Endpoints: 
1=annual exacerbation rate    6=mean annual change in EDSS 
2=proportion of relapse-free patients   7=median time to progression 
3=number of patients who progressed at 2 years 8=mean time to progression 
4=median time to first relapse   9=number of relapses per patient 
5 =exacerbation duration and severity  10=relapse severity 
 
Note: Results are as compared to placebo-group.Total over 2 years.  ** Gd+ lesions—
gadolinium-positive lesions. ***T1 black holes represent axonal loss and demyelination. 
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Table 5. Treatment Recommendations of the Medical Advisory Board of the NMSS on  
  the Use of IFNB-1a IM, IFNB-1a SC,  IFNB-1b, and Glatiramer Acetate 
 
? Initiation of therapy is advised as soon as possible following a definite diagnosis    
            of MS with active disease, and may also be considered for selected patients with  
            a first attack who are at high risk of MS  
? Patients’ access to medication should not be limited by the frequency of relapses,  
            age, or level of disability 
? Treatment is not to be stopped during evaluation for continuing treatment 
? Therapy is to be continued indefinitely except for the following circumstances:   
            there is a clear lack of benefit; there are intolerable side effects; better therapy   
            becomes available.  
? All of the FDA-approved agents should be included in formularies and covered by 
third party payers so that physicians and patients may determine the most 
appropriate agent on an individual basis—failure to do so is unethical and 
discriminatory 
? Movement from one immunomodulator drug to another should occur only for  
            medically appropriate reasons 
? Immunosuppressant therapy with Novantrone © (mitoxantrone) may be 
considered for selected relapsing patients with worsening disease or patients with 
secondary-progressive multiple sclerosis 
? Most concurrent medical conditions do not contraindicate use of the 
immunomodulatory drugs 
? None of these therapies has been approved for use by women who are trying to 
become pregnant, are pregnant, or are nursing mothers 
                
 
Source: National MS Society. Available at: 
http://www.nationalmssociety.org/docs/HOM/EXP_Consensus.pdf  
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Table 6. Most common side effects related to the DMDs 
 
 IFNB-1b 
(25 mg) 
IFNB-1a IM 
(30mcg) 
IFNB-1bSC 
(44 mcg) 
Glatiremar 
Acetate 
(20mg) 
Injection site 
reactions 
85% 8% 92% 73% 
Headache 57% 58% 70% 5% 
Flu-like 
symptoms 
60% 49% 59% 19% 
Pain 51% 23% --- --- 
Fatigue --- --- 41% --- 
Myalgia 27% 29% 25% --- 
Fever 36% 25% 28% 8% 
Depression 34% 18% --- --- 
Palpitations  --- --- 17% 
Chest pain  --- --- 21% 
Dyspnea  --- --- 19% 
Lymphocyte 
abnormality 
88% --- --- --- 
 
Source: Data on file (Berlex laboratories, 2003; Biogen Inc, 2003; Serono Inc, 2004; 
Teva Neuroscience, 2004) 
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Table 7. Conceptual definitions from the Beliefs About Medicines Framework 
Concept  Definition Operational definition 
Treatment Necessity Belief that a particular 
medicine is necessary 
 
for treatment 
Belief About Medicines 
   Questionnaire 
Qualitative Interview: 
-  Subjective Experiences 
-Symptom Experience 
-  Benefits of    
     Immunomodulators 
- Illness representation         
- Health Care  Provider       
      Influence  
                                      
Perceived Concerns Anticipations of unpleasant 
side effects or disruptions 
by a particular medication 
-Beliefs About Medicines  
    Questionnaire 
Qualitative Interview: 
-Subjective experiences 
-Barriers: 
        -adverse effects 
        -finances 
        -injection issues 
        -lack of efficacy 
        -intrusiveness 
-Health Care Provider  
     influence       
Necessity-Concerns 
Differential 
The balance between 
treatment necessity and 
specific concerns about the 
prescribed medicine, 
determined using a cost-
benefit appraisal 
 
Beliefs About Medicines 
Questionnaire: calculated 
difference between 
treatment necessity and 
perceived concerns.  
 
 Source:  Horne, R. (1997). Representations of medication and treatment: Advances in  
theory and measurement. In K.J. Petrie & J. A. Weinman, Perceptions of health & 
illness. The Netherlands: Harwood Academic Publishers, 155-188. 
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Table 8: Demographic Characteristics of the Sample 
 
Demographic Mean Range SD 
Age 47 32-66 years 7.35 
Time with 
RRMS 
(Months) 
99 8-348 months 96.7 
Time on IIM 
Treatment 
(months) 
37 4-132 months 30.5 
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Table 9: Types and usage of Injectable DMDs 
DMD  Frequency (n) Percentage 
IFNB-1a IM (Avonex) 15 60 
Glatiremar acetate 
(Copaxone) 
6 24 
IFNB-1b (Betaseron) 2 8 
IFNB-1a SQ (Rebif 2 8 
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Table 10. Symptoms Reported by Participants 
 
Symptoms Frequency (n) Percentage 
Fatigue 16 50% 
Difficulty walking  14 44% 
Cognitive issues 13 41% 
Numbness  11 34% 
Weakness 7 22% 
Vision problems 7 22% 
Leg pains/spasms 6 19% 
Tingling  6 19% 
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Table 11. Symptoms of RRMS and Strategies 
  
Symptom Strategies 
Fatigue Nap, relax, rest, ‘take down time’, ‘push through the fatigue’, ‘slow down’, 
change work habit,  avoid warm weather, ask for help 
Walking 
difficulty 
Don’t walk long, monitor legs, ‘wait for feet’, use support (carriage), don’t walk 
alone, play indoors with grandchildren, stop aerobics, start exercise  
Cognitive 
issues 
Write things down,   re-read information multiple times 
Numbness Avoid very warm water, minimize stress 
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Table 12. Common Injectable DMDs Issues and Strategies 
 
IIM issues Strategies 
Planning Calendar, schedule 
Rotating sites Create a grid of sites, Leave bandaid on the last 
site 
Injection pain Ice, EMLA (anesthetizing cream) Analgesics 
(acetaminophen, ibuprophen) 
Injection site lumps Ice, rotate sites 
Injection site itchiness Cortisone cream 
Injection phobia Have others inject, Inject slowly, quiet place 
Travel Get supplies, guidance from IIM company 
Flu-like side effects Inject at night, acetaminophen, ibuprophen,  
 
Schedule sufficient rest, hydration 
Severe side effects Avoid arms, use buttocks 
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Table 13. Results from the Beliefs About Medicines Questionnaire 
Belief Mean Median SD 
Present health depends on 
injectable DMD 
3.06 3.00 1.29 
Life impossible without 
injectable DMD 
2.19 2.00 1.15 
Very ill without injectable 
DMD 
2.78 3.00 1.16 
Future health depends on 
injectable DMD 
3.44 4.00 1.19 
Injectable DMD protects 
from getting worse 
4.00 4.00 1.14 
Worries about using 
injectable DMD 
2.88 2.00 1.48 
Worries about long term 
effects of injectable DMD 
3.38 4.00 1.41 
Injectable DMD is a 
mystery 
2.50 2s00 1.02 
Injectable DMD disrupts 
life 
2.13 2.00 1.34 
Worries about becoming 
dependent on the injectable 
DMD 
1.66 1.50 1.50 
 
Note: Statements were on a 5-point Likert scale; 1= strongly disagree; 5= strongly agree. 
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Table 14. Necessity-Differential Scores. 
 
 
Participant  Tx Status  
 ID  
  
Necessity-
Differentials 
Score 
1 On Tx -5 
2 On Tx +1 
3 On Tx -9 
4 On Tx +6 
 
 
 
 
 
 
 
 
   5 On Tx +8  
 6 On Tx +5  
 
7 On Tx +1  
 
8 On Tx  +12 
 
9 On Tx +6  
 
10 On Tx +7  
 
11 On Tx +9  
 
12 On Tx -4  
 
13 On Tx +5  
 
14 On Tx +13  
 
15 On Tx +1  
 
16 On Tx  
 
 
+14 
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Participant 
ID 
Tx  Status Necessity-
Differentials 
Score 
 
 17 On Tx +9 
 18 On Tx +6 
 19 Off Tx -8 
 
20 On Tx +6 
 
21 On Tx +5 
 
22 On Tx +3 
 
23 Off Tx -14 
 
24 On Tx +2 
 
25 Never on Tx -5 
 
26 Off Tx -13 
 
27 On Tx +4 
 
28 On Tx +5 
 
29 Off Tx -7 
 
30 On Tx +11 
 
31 On Tx +8 
 
32 On Tx 
 
+12 
Note: Status on Treatment: On treatment (on Tx); 
Off treatment (off Tx); never on treatment (never on Tx). 
Necessity Differentials-score: positive scores signify greater  
necessity beliefs; negative scores signify greater concerns. 
Bolded row indicates negative score for a woman on treatment. 
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Table 15. Pros and Cons related to the injectable DMDs 
 
 
Pros  n Percent Cons n Percent 
Doesn’t want to get 
worse 
8 32% Side Effects 9 36% 
No side effects 6 24% Uncertainty  7 28% 
Hope 6 24% Hates needles  5 20% 
No relapses  5 20% Injection site reactions 5 20% 
Mild  or no SE 5 20% Painful injections 5 
 
20% 
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Appendix A.    Qualitative Interview Guide (Users) 
 
       Subject # _______ 
               Date __________ 
 
 
Conceptual Area                 Interview Question                                  Probes 
 I.  Subjective 
experience of day-to-day 
management with 
injectable 
immunomodulators 
  
Can you tell me your story 
related to RRMS? 
How has your life changed 
since you were diagnosed 
with RRMS? 
  Can you tell me what it’s like 
for you to use the injectable 
immunomodulator?  
a) Tell me about any special 
routine you have concerning 
your injection?  
b)  Have you made any 
changes over the last month 
with your injection routine? 
c) What factors (if any) have 
made it easy for you to 
manage your injectable 
DMD? 
Ia. Perceived Barriers Is there anything that makes it 
hard for you to use or continue 
your injections? 
a) Do you have any 
problems giving yourself the 
injection? 
b) Have any side effects 
made it hard for you to use 
or continue your injections? 
c) Have insurance or money 
issues made it hard for you 
to use or continue your 
injections? 
Ib. Adherence issues What is your experience with 
missed or skipped doses of the 
injectable immunomodulator?   
a) Some people have told 
me that they sometimes skip 
their injection, forget to take 
it, or change the dose. Has 
anything like this happened 
to you?  
b) Some people have told 
me that they sometimes stop 
taking their injection for a 
while. Has anything like this 
happened to you? 
IIa. Treatment Necessity   How have things changed 
since you started the 
injections?  
a) Since you started your 
injections, do you think your 
RRMS has improved? 
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Worsened? Remained the 
same? 
b) What do you see as the 
greatest benefits of the 
injection?  
c) What have you been told 
about the benefits of the 
injection medication?  
d) What do you think would 
happen if you weren’t using 
the injection medication? 
 
IIb. Specific Concerns What concerns you about the 
injections? 
a) What have you been told 
about the negative aspects 
of the injections?  
b) Some people have said 
that the injections have 
disrupted their lives. Has 
anything like that happened 
to you? 
c) What have you done 
about your concerns?  
d) Have you thought about 
your long-term plans with 
the injection medication? 
IV. Health Care 
Provider influence on 
injectable 
immunomodulator  day-
to-day management 
How do your doctors and 
nurses influence how you 
manage your injection 
medication? 
a)  What was your 
discussion with the HCP 
like when you decided to 
start the injection therapy? 
b) Do you feel you spend 
enough time talking about 
the injectable medication 
during your visit? 
c) Have you ever called 
your HCP when you have 
had problems with your 
therapy? 
d) Have you ever discussed 
stopping therapy or ‘taking 
a break’ from therapy with 
your HCP?  
e) What advice would you 
give HCPs about helping 
patients like yourself to 
manage the injection 
medication?  
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Appendix B.   Qualitative Interview Guide (Discontinued use) 
 
       Subject # _______ 
               Date __________ 
 
 
Conceptual Area                 Interview Question                                  Probes 
 I.  Subjective 
experience of day-to-day 
management without 
injectable 
immunomodulators 
  
Can you tell me your story 
related to RRMS? 
 
How has your life changed 
since you were diagnosed 
with RRMS? 
Ia. Perceived Barriers What made it hard for you to 
continue your injections? 
 
a) Did you have any 
problems giving yourself the 
injection? 
c) Did any side effects make 
it hard for you to use or 
continue your injections? 
e) Have insurance or money 
issues made it hard for you 
to use or continue your 
injections? 
Ib. Adherence issues Prior to stopping, what was 
your experience with  missed 
or skipped doses of the 
injection? 
 
 
a) Some people have told 
me that they sometimes 
forget to take their injection. 
Did anything like that 
happen to you?  
b) Some people have told 
me that they sometimes skip 
their injection or change the 
dose. Did anything like this 
happen to you?  
c) Some people have told 
me that they sometimes stop 
taking their injection for a 
while. Did anything like this 
happen to you? 
IIa. Treatment Necessity   How did things change when 
you started the injections? 
How have things changed 
since you stopped the 
medication? 
 
 
a) Since you started your 
injections, did you think 
your RRMS had improved? 
Worsened? Remained the 
same? 
b) What did you see as the 
greatest benefits of the 
injection?  
c) What were you told about 
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the benefits of the injection 
medication?  
d) Do you think anything is 
different because you aren’t 
using the injectable 
immunomodulators? 
 
IIb. Specific Concerns What concerned you about the 
injection? 
 
 
a) What do you know about 
the negative aspects of the 
injections?  
b) Some people have said 
that the injections have 
disrupted their lives. Did 
anything like that happen to 
you? 
c) What did you do about 
your concerns?  
d) Have you thought about 
your long-term plans with 
your medication decisions? 
IV. Health Care 
Provider influence on 
injectable 
immunomodulator  day-
to-day management 
How did your doctors and 
nurses influence how you 
managed your injection 
medication? 
 
 
a)  What was your 
discussion with the HCP 
like when you were 
deciding whether to start the 
injection therapy? 
b) Did you spend any time 
talking about the injectable 
medication during your 
visits? 
c) Did you ever call your 
HCP when you had 
problems with your therapy?
d) Did you ever discuss 
stopping therapy or ‘taking 
a break’ from therapy with 
your HCP?  
e) What advice would you 
give HCPs about helping 
patients like yourself to 
manage the injection 
medication?  
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Appendix C. Qualitative Interview Guide (Never used)  
 
Conceptual Area                        Interview Question                                  Probes 
I.  Subjective experience of 
day-to-day management 
without injectable 
immunomodulators 
  
Can you tell me your story 
related to RRMS? 
 
a) How has your life 
changed since you were 
diagnosed with RRMS? 
b) Have you had any 
changes in your RRMS over 
the last  year? 
c) How did you come to the 
decision not to start the 
injectable medications? 
 
Ia. Perceived Barriers Is there anything that has 
made it hard for you to 
begin to use injectable 
medications? 
 
 
 
a) Have insurance or 
money issues made it 
hard for you to start 
using injections? 
b) Have family issues 
made it hard for you to 
start using injections? 
IIa. Treatment Necessity        What do you think are the 
benefits to the injectable 
medications?  
a) What do you know about 
the benefits of the injectable 
medications?  
b) Where do you/have you 
gotten information about 
the injectable medications?  
b) Do you think anything is 
different with your RRMS 
because you aren’t using the 
injectable medicaitons? 
 
IIb. Specific Concerns What concerned you about 
the injectable medications? 
 
 
a) What concerns you about 
the  injectable medications? 
b) What have you been told 
about the negative aspects 
of the injections?  
c) What did/have you done 
about your concerns?  
d) Have you thought about 
your long-term plans with 
your  medication decisions? 
 
 
IV. Health Care Provider 
 
 
How do (have) your doctors 
 
 
a)  What was your 
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influence on injectable 
immunomodulator  day-to-
day management 
and nurses influence(d) 
your decision regarding 
injectable medication? 
 
discussion with the HCP 
like when you were 
deciding whether to start the 
injection therapy? 
b) Did/do you feel you 
spend enough time talking 
about the injectable 
medication during your 
visit? 
 
b) What advice would you 
give HCPs about helping 
patients like yourself to 
manage the injectable 
medication?  
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Appendix D.   Demographic Data Sheet  
Subject # ________ 
                                                                                              Date ________ 
 
The following information will be collected during patient interview: 
1. Age at last birthday: _______ years  
2.   Gender                                                                 
       Male  ____________       ( )1                               
                                                                                           Female___________       ( )2 
                                                                                   3.   Race/ethnicity: 
__   Caucasian/White____      ( )1                             
__   African American___      ( )2             
__   Hispanic____________   ( )3               
       Asian American               ( )4        
__   Native American______  ( )5 
__   Other _______________ ( )6   
If other, please specify ____________ 
4.   Marital Status: 
___  Married_____________( )1                                
____Widowed___________ ( )2   
____Single______________( )3  
____Separated___________( )4  
____Divorced___________ ( )5  
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Subject # ________ 
                                                                                              Date    ________ 
 
 
 ____Living with Partner__ ( )6   
                   ____Other_____________ ( )7  
                                                                                             If other, please specify:__ 
                                                                                   __________________________                                
5.  Occupation: 
____Working full-time____( )1                  
____Working part-time___ ( )2                
____On leave from work__ ( )3               
____On disability________( )4                         
                                                                                    ____ Retired____________( )5           
_____Student___________( )6                        
_____Other____________ ( )7        
_____If other, please specify:_   
_________________________ 
 
 
 
 
 
 
 
  164  
Subject # ________ 
                                                                                              Date ________ 
 
6.  Insurance Status:  
__   Private__________       ( )1               
___ Medicare___________ ( )2 
___ Medicaid___________ ( )3 
___ No insurance________ ( )4           
___ Don’t know/ 
       Don’t remember_____  ( )5         
       ___Other_______________( )6    
                                                                                   ____If other, please specify:___ 
__________________________ 
7. Education:   
        ___# Years completed:________ 
___Don’t know/ 
___Don’t remember_______( )1 
8. Diagnosis of RRMS: 
  __  # Years with RRMS:______ 
  ___Don’t Know/ 
  ___Don’t remember_______( )1   
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Subject # ________ 
                                                                                              Date ________ 
   
 
  9. Worsening Disease: 
  ___# Relapses over the last year:___ 
  ___Don’t know 
  ___ Don’t remember________  ( )1 
10.  Immunomodulator Treatment 
___# Years on injectable Rx: ____  
___Don’t Know/ 
     Don’t remember__________( )1 
11. Type of injectable Rx currently    
          using:   
       ___ Avonex______________ _( )1  
____Rebif_________________ ( )2 
___Betaseron_____________   ( )3 
___Copaxone______________ ( )4  
 ___None__________________( )5 
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Subject # ________ 
                                                                                              Date ________ 
 
 
12. Types of injectable Rx used  
____before: (List all) 
___ Avonex______________ _( )1  
___ Rebif_________________ ( )2 
___Betaseron_____________   ( )3 
___Copaxone______________ ( )4  
 ___None__________________( )5 
___Don’t know/ 
___Don’t remember_________( )6 
13. Adherence:  In the past month,  
how often did you miss your 
MS medication?   
        ____Did not miss any doses___( )1  
____Missed one or more doses( )2  
        ____Don’t know/ 
____Don’t remember________( )3 
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Subject # ________ 
                                                                                              Date ________ 
 
   14. Where do you go for information  
         about your illness (RRMS)  
          and/or injectable medication?   
                                           (Please rank in order of   
                                                 preference) 
        ___Health care provider/  
___(MD, NP, PA)         _ ( )1 
___Health care staff/ 
 (RN, LPN)___________( )2 
___Books, pamphlets, 
          Magazines_______( )3                        
___Websites__________ ( )4      
___Support groups_____ ( )5 
___Others with RRMS__( )6 
___Other_____________( )7  
 If other, please explain ________ 
                                                                                    ___________________________ 
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Appendix E.  Beliefs About Medicines Questionnaire    
Subject # ____  
Date  ____ 
Scale:   
(1)  Strongly Disagree   
(2)  Disagree  
(3)  Uncertain  
(4)  Agree   
(5)  Strongly Agree  
 
BMQ—Specific Necessity                           
_____  1. My health, at present, depends on my injectable medicine.                                                          
_____  2. My life would be impossible without my injectable medicine.  
_____   3. Without my medicines I would be very ill. 
_____  4. My health in the future depends on my injectable medicine. 
_____  5. My injectable medicine protects me from becoming worse. 
 
BMQ—Specific Concerns 
 _____  1. Having to take the injectable medication worries me. 
 _____  2. I sometimes worry about long-term effects of my medicines. 
 _____  3. My injectable medicine is a mystery to me. 
 _____  4. My injectable medicine disrupts my life. 
 _____  5. I sometimes worry about becoming dependent on my injectable medicine. 
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